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Aspects of protein phosphatase regulation 
Jennifer Marie Imparl Radosevich 
Major Professor; Dr. Donald J. Graves 
Iowa State University 
Aspects of regulation of two protein phosphatases involved 
in signal tranduction are described in this dissertation. The 
first phosphatase, calcineurin, is involved in T-cell activation 
and is also regulated by Ca2+/calmodulin. Because most studies 
on the interaction between calmodulin and the enzymes which it 
activates have focused on the role of hydrophobic residues in 
the interaction, we have instead focused on the role of the 
positively charged arginine residue in calcineurin-calmodulin 
interaction. To this end, certain arginine residues in the C-
terminal portion of calcineurin were converted to the neutral 
amino acid citrulline by the action of peptidylarginine 
deiminase. The resulting loss of phosphatase activity and 
decreased calmodulin activation of calcineurin was due to an 
apparent reduced affinity of calmodulin for deiminated 
calcineurin. We conclude that at least one arginine in 
calcineurin is important for calmodulin binding and is likely 
located at the calmodulin binding site of the calcineurin 
catalytic subunit. 
Further localization of the citrulline modifications were 
attempted by expressing a recombinant calcineurin catalytic 
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subunit in which the C-terminal 43 residues have been deleted. 
Deimination of this truncated calcineurin, which lacks four 
arginine residues, results in the incorporation of 0.5 mol/mol 
less citrulline than full-length calcineurin and no loss of 
activity. This may indicate that an arginine not present in the 
truncated calcineurin is normally deiminated in the full-length 
calcineurin and results in reduced calmodulin activation and/or 
binding to full-length calcineurin. 
The second phosphatase described in this dissertation is 
PTP-1, a homolog of a tyrosine phosphatase thought to be 
involved in the attenuation of the insulin signal. The activity 
of PTP-1 was found to be inhibited in vitro by compounds derived 
from cinnamon, compounds which potentiate insulin's effects. 
One fraction derived from cinnamon is an irreversible 
inactivator of PTP-1. Another compound which inhibits PTP-1 has 
a molecular weight of 346. The cinnamon compounds were found to 
also stimulate insulin receptor kinase catalytic 
autophosphorylation in vitro. Therefore, the compounds may 
serve a dual role in insulin signalling. They may act to 
stimulate insulin receptor signalling by causing activation of 
its autophosphorylation while inhibiting a PTPase(s) which would 
attenuate the kinase signal. 
ii 
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GENERAL INTRODUCTION 
Calcineurin/ a calmodulin-activated phosphatase 
Calcineurin subunit composition 
Calcineurin (CaN) is a major soluble calcium and calmodulin 
(CaM) binding protein found in brain extracts (1,2). First 
identified as an inhibitor of calmodulin-stimulated cyclic 
nucleotide phosphodiesterase because it competed for calmodulin 
binding (2-4), calcineurin was later shovm to have Ca^+ZCaM-
regulated phosphatase activity (5,6). A heterodimeric enzyme, 
calcineurin is composed of a 1:1 complex of a large subunit, CaN 
A, Mr 58-61 kDa, and a small subunit, CaN B, Mr 15-19 kDa 
(2,7,8). CaN A contains the catalytic site (9) and sole 
calmodulin binding domain (1), whereas CaN B has 35% sequence 
identity to calmodulin (10) and binds four calcium ions with 
micromolar affinity (1). Recently shown to have highly 
homologous secondary structure to calmodulin (11), CaN B is 
thought to play a regulatory role in conferring additional 
calcium sensitivity to the enzyme In vivo (12). 
Domain organization of calcineurin 
Limited proteolysis of calcineurin by certain proteases has 
facilitated the domain mapping of CaN A, while CaN B seems 
resistant to the proteolytic enzymes utilized (13-16). In these 
experiments, it was shown that the CaN A subunit contains 
distinct CaN B-binding, CaM-binding, and autoinhibitory domains. 
The CaN B-binding domain is located on a 44-kDa N-terminal 
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catalytic core, whereas the CaM-binding and autoinhibitory 
domains are found on a 14 kDa C-terminal fragment (16). The 
CaM-binding and autoinhibitory domains have also been confirmed 
using sequence homology for the CaM-binding domain (17) and 
peptide inhibition studies for the autoinhibitory domain (18). 
The 44 kDa proteolytic fragment is catalytically active but is 
insensitive to activation by Ca^+ZcaM (13-16). 
Substrates of CaN 
Calcineurin has been shown to dephosphorylate several 
protein substrates (8,19-21), including the a-subunit of 
phosphorylase kinase and protein phosphatase inhibitor-1 (5), 
although the physiological relevance of the dephosphorylation of 
any of the substrates surveyed is unknown. In addition to 
Ser/Thr phosphatase activity, calcineurin also shows phosphatase 
activity toward some phosphotyrosyl proteins and peptides, among 
these the epidermal growth factor (EGF) receptor (22), but most 
phosphotyrosyl protein are poorer substrates for calcineurin 
than their serine or threonine phosphate counterparts (23). 
However, in the case of low molecular weight phosphate esters, 
phosphotyrosine esters are dephosphorylated readily, while 
phosphothreonine and phosphoserine are not significantly 
dephosphorylated (24). Perhaps the most useful of the low 
molecular weight phosphate esters is p-nitrophenylphosphate 
(pNPP), because hydrolysis of pNPP results in the chromogenic 
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product p-nitrophenol which can be used to monitor calcineurin 
activity spectrophotometrically. 
Another of calcineurin's substrates has received much 
attention recently because of its apparent role in Alzheimer 
disease. Abberant phosphorylation of tau in the Alzheimer 
condition has been linked to formation of abnormal aggregation 
of paired helical filaments called neurofibrillary tangles 
(25,26). Calcineurin has been shovm to be able to 
dephosphorylate this abnormally phosphorylated tau in vitro 
(27,28), suggesting that regulation of this enzyme could be 
involved in Alzheimer's. Although the overall levels of the 
calcineurin protein are not significantly different between 
Alzheimer and control brain tissue (29), nothing is known about 
the levels of calcineurin phosphatase activity in the diseased 
state. 
Regulation of calcineurin by metal ions 
The phosphatase activity of purified calcineurin, in 
addition to being calmodulin-stimulated, is further stimulated 
by certain divalent ions, the most efficient of these being Mn^^ 
and Ni2+ (30-32). There is evidence that Mn2+ and Ni2+ activate 
the phosphatase activity of calcineurin by different mechanisms. 
Matsui et al. (33) suggest that Mn^"*" and Ni2+ induce different 
active conformations of calcineurin, since Ni2+-stimulated 
calcineurin activity could be inhibited upon addition of a 
monoclonal antibody specific for CaN B, but Mn^^-stimulated 
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calcineurin was not inhibited by the antibody. Perhaps stronger 
evidence for different conformations of Mn2+- and Ni2+-activated 
calcineurin involves the study of the 44 kDa catalytic core of 
calcineurin and its regulation by a peptide corresponding to the 
autoinhibitory region of calcineurin (34). In that study, the 
autoinhibitory peptide inhibited the Mn2+-stiinulated catalytic 
core by 80%, while the peptide had little effect on the Ni2+-
stimulated catalytic core activity. Although no detectable Ni2+ 
or Mn2+ can be found in calcineurin immunoprecipitated from 
bovine brain extracts (35), Ni2+ and Mn2+ remain to be used 
routinely in laboratories for calcineurin activity assays. 
Regulation of calcineurin by immunosuppressants 
The involvement of calcineurin in T-cell signalling was 
confirmed with the discovery that calcineurin is the target of 
the immunosuppressants FK506 and cyclosporin A (CsA) with their 
respective receptors, FKBP and cyclophilin (CyP) (36-38). The 
binding of FK506-FKBP or CsA-CyP complex to calcineurin inhibits 
its phosphatase activity (37,38) and, in turn, inhibits T-cell 
activation as assessed by decreased IL-2 production (37,39). It 
is thought that the inhibition of T-cell activation with 
immunosuppressant treatment occurs as a result of the inability 
of the inhibited calcineurin to dephosphorylate NF-AT, a T-cell 
transcription factor which regulates IL-2 gene synthesis (40). 
This is because calcineurin has been shown to be able to 
dephosphorylate NF-AT in vitro (41,42), and dephosphorylation of 
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NF-AT is associated with its translocation from the cytoplasm to 
the nucleus (41). Consistent with this model, FK506 or CsA 
blocks NF-AT translocation to the nucleus (41,43), where it can 
bind DNA and regulate lL-2 production. Conversely, 
overexpression of calcineurin in Jurkat cells, a human T-cell 
line, makes them more resistant to FK506 or CsA (44,45) and 
increases NF-AT dependent transcription (45). 
Recently, the sequence and structural aspects of 
calcineurin required to bind to the immunophilin-drug complex 
have been studied. The CaN B subunit is absolutely required for 
binding of drug complex (46,47). However, CaN B is not 
sufficient for drug complex binding, since minimal sequences in 
CaN A, sequences in CaN A identified as the CaN B binding site 
(48), are also required (46,47). The reason for this became 
apparent when it was found that the "latch region" of CaN B, a 
region of tertiary structure formed only when CaN B binds CaN A, 
plays an important role in drug complex binding and CaN A 
catalytic activation, as determined by site-directed mutagenesis 
(49). Additional sequences in CaN A also may be important in 
immunophilin-drug complex binding, since the autoinhibitory 
domain and FK506-FKBP binding sites on the CaN A subunit appear 
to overlap (50,51). 
Regulation of calcineurin by calmodulin 
Calmodulin, a ubiquitous calcium-binding protein, binds to 
and activates several known enzymes (52,53). Like CaN B, it 
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binds 1 Ca2+ ion in each of 4 "EF-hand" binding loops, for a 
total of 4 mol Ca^+Zmol (54,55). X-ray structure determination 
of calmodulin shows that the protein is dumbbell shaped, with 
two globular domains separated by a central a-helical tether 
(55). Each globular domain contains 2 EF-hands. While 
calmodulin is not bound to a target, the central helix is 
flexible (56). However, when calmodulin is bound to a target 
peptide of smooth muscle myosin light chain kinase (smMLCK), the 
central helix is bent, with the two globular domains making 
various contacts with the peptide (57,58). 
Although characterized calmodulin binding domains in 
calmodulin-activated enzymes show considerable sequence 
diversity, most are predicted to form basic amphiphilic a-
helices (59). The putative calmodulin binding domain of 
calcineurin is also predicted to form such a helix (17), and 
there is evidence that calcineurin binds to calmodulin most 
similarly to smMLCK. For example, crosslinking calmodulin's 
globular domains together so that the central helix is bent as 
in the calmodulin-smMLCK peptide complex has no effect on its 
ability to activate calcineurin (60). Additionally, an 
especially important sequence of the calmodulin-binding domain 
of smMLCK, VRAIGR, bears a striking resemblance to a portion of 
the calmodulin-binding domain of calcineurin, IRAIGK. This 
extent of sequence homology in calmodulin binding domains is not 
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observed in comparing the sequences of any other calmodulin-
stimulated enzymes (58). 
However, there are clear differences between the mechanism 
of binding and activation of calcineurin by calmodulin and that 
of some other calmodulin-dependent enzymes. For example, the 
autoinhibitory domain of calcineurin is thought to be 50-60 
residues C-terminal to the putative CaM-binding domain 
(17,18,61). This situation is different from that of smMLCK 
(62) and CaM-kinase II (63), where the autoinhibitory region is 
adjacent to and slightly overlapping the CaM-binding domain. In 
another observation, a mutant calmodulin with 19 amino acid 
substitutions could half-maximally activate calcineurin, but 
could not activate phosphorylase kinase at all (64). 
Many studies on the interaction between calmodulin and the 
enzymes which it activates have focused on the role of 
hydrophobic residues either in the enzyme (58,65) or in 
calmodulin itself (56,57,66,67). X-ray crystal (56) and NMR 
solution (57) structures of calmodulin bound to a peptide of 
smMLCK show that the binding of calmodulin to its target is 
probably dominated by van der Waals forces. However, not much 
is known about the importance of electrostatic interactions in 
calmodulin-target binding. Although Meador et al. (56) observed 
that 80% of the contacts between calmodulin and the smMLCK 
peptide were of the van der Waals type, they also noted that all 
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seven basic residues of the smMLCK peptide make salt bridges 
with calmodulin. 
Role of arginyl residues in calcineurin 
Chemical modification of arginyl residues by phenylglyoxal 
has provided limited knowledge of the role(s) arginine plays in 
calcineurin function (68). A time- and concentration-dependent 
inactivation of calcineurin activity is seen when calcineurin is 
reacted with phenylglyoxal. The enzyme is protected from 
phenylglyoxal inactivation partially by ADP, a competitive 
inhibitor of calcineurin, and completely by pNPP, a substrate of 
the phosphatase. This suggests that arginine is important for 
catalytic activity in or near the catalytic site of the enzyme. 
Kinetic analysis of the order of the inactivation indicates that 
only one modified arginine may be responsible for the observed 
loss of activity. However, inactivation of calcineurin with 
radioactively labeled phenylglyoxal results in the incorporation 
of 12 equivalents of phenylglyoxal, making identification of the 
relevant arginine difficult (68). 
Peptidylarginine deiminase 
Peptidylarginine deiminase has been used to enzymatically 
convert arginine residues in proteins and peptides to citrulline 
(69-71). Citrulline is formed from arginine by the loss of a 
single amino group at the end of the side chain, which results 
in the loss of the positive charge but does not drastically 
alter the structure of the side chain. The conversion can cause 
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significant changes in the function of target protein in vitro 
(10,11). Because a bulky group, such as phenylglyoxal, is not 
introduced into the modified protein, effects due to steric 
hindrance of the modified group on the protein can be 
discounted. Therefore, peptidylarginine deiminase is a useful 
probe in studying the role of the positive charge of arginine's 
guanidino group by conversion of it to a neutral amino acid 
which cannot be introduced by simple site-directed mutagenesis. 
The physiological function of peptidylarginine deiminase is 
still not clear; however, its expression has been found to be 
regulated by estrogen (72) and the estrous cycle (73,74). 
Insulin signalling and regulation 
Insulin receptor kinase 
The insulin receptor kinase (IRK) is a heterotetramer, 
consisting of two extracellular a-subunits disulfide-linked to 
two p-subunits (ap)2. The p-subunits contain a single 
transmembrane domain, a cytoplasmic tyrosine kinase domain, and 
a regulatory C-terminal domain (75,76). Insulin binding to the 
extracellular a-subunits of the insulin receptor kinase 
presumably causes a conformational change in the tyrosine kinase 
domain of the p-subunits, resulting in the activation of the 
insulin receptor's kinase activity. The activation of IRK 
causes autophosphorylation of the kinase on several tyrosines: 
Tyr-1158, Tyr-1162, and Tyr-1163 in the kinase region (77-81), 
Tyr-1328 and Tyr-1334 in the C-terminal tail (77,78), and one or 
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more of Tyr-965, Tyr-972, and Tyr-984 in the juxtamembrane 
region (81). These autophosphorylations of IRK on tyrosines are 
believed to occur via a trans-mechanism, i.e. the kinase domain 
of one p-subunit phosphorylates tyrosine residues on the 
adjacent p-subunit (82,83). After autophosphorylation, the 
insulin receptor kinase is activated toward exogenous substrates 
(77,79,80). 
Recently, the X-ray structure of an inactive form of the 
kinase domain of the human insulin receptor has been determined 
(84). The general structure of IRK is similar to that of cAMP-
dependent protein kinase (cAPK). The authors observed a smaller 
N-terminal lobe connected to a larger C-terminal lobe, with a 
cleft in the middle of the lobes. However, the relative 
orientation of the lobes in the IRK is quite different from that 
of cAPK because the N-terminal lobe of IRK is rotated 26° 
relative to closed-form cAPK and a wider cleft between the two 
lobes exists. The most striking feature of the crystal 
structure, though, is the presence of Tyr-1162 in the active 
site cleft. The tyrosine is not phosphorylated, presumably 
because the orientation of its binding precludes ATP binding in 
the active site. The authors postulate, then, that Tyr-1162 
binds to the active site of IRK to inhibit its activity while 
insulin is not bound to the receptor. When insulin is bound to 
the receptor, then a conformational shift conferred to the p-
subunit could displace the inhibitory Tyr-1162, allowing ATP to 
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bind and tyrosines in the adjacent p-subunit to be 
phosphorylated. 
Insulin receptor kinase down-regulation and 
internalization 
As soon as activation of the insulin receptor kinase and 
propagation of the insulin signal begins, so does down-
regulation of the insulin-receptor complex by a process termed 
"receptor-mediated endocytosis" (85). This means that insulin 
actually triggers internalization of its own receptor to a 
network of tubules and vesicles called endosomes. This 
internalization has been shown to require receptor kinase 
activation and autophosphorylation on tyrosine, since cells 
expressing kinase-deficient receptors exhibit impaired insulin 
internalization (86). 
The binding of insulin to its receptor does not occur 
randomly along the cell surface; instead, the initial binding of 
insulin occurs on thin digitations called microvilli (87,88). 
After insulin binding to the receptor, the insulin-receptor 
complex is redistributed to the nonvillous surface of the cell 
and is concentrated in clathrin coated pits (87,88). 
Association of the insulin-receptor complex with clathrin coated 
pits requires specific sequences in the juxtamembrane domain of 
the p-subunit (89-91) and sequences in the transmembrane domain 
itself (92). The insulin-receptor complex then actually enters 
the cell through invagination of the clathrin coated pit and 
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fission from the plasma membrane to form an internalized 
clathrin-coated vesicle (87). Fusion of the complex with the 
endosome follows. Once the insulin-receptor complex has entered 
the endosome, the acidic environment of the lumen of the 
endosome allows dissociation of insulin from the receptor 
(93,94). The dissociated insulin is targeted to the lysosomes 
to be degraded (95), while the receptor is recycled back to the 
cell surface to participate again in insulin signalling (96). 
IRS-1 
A number of proteins in the cell are phosphorylated in 
response to insulin stimulation (97). One of these, ppl85 or 
insulin-receptor substrate-1 (lRS-1), is a principal substrate 
of the receptor kinase (98). IRS-1 has not been shown to have 
any intrinsic enzymatic activity, but seems to constitute a 
unique signal transduction protein (99). Synthetic peptides 
based on amino acid sequence of IRS-1 serve as excellent 
substrates for the receptor kinase in vitro (100). The entire 
amino acid sequence of IRS-1 has been deduced, and it reveals 
that over 20 potential tyrosine phosphorylation sites exist in 
the sequence (99). At least 8 of these sites have been shown to 
be actually phosphorylated by the receptor kinase in vivo (101). 
Proteins which interact with IRS-1 
Phosphatidvlinositol 3'-kinase (PI 3'-kinase 
Phosphatidylinositol 3'-kinase (PI 3'-kinase) was the first 
protein found to associate with IFlS-1 (102-104). PI 3'-kinase 
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phosphorylates phosphatidylinositol at the D-3 position of the 
inositol ring (105), but the most important product of PI 3'-
kinase may be phosphatidylinositol (3,4,5)-trisphosphate (PIP3) 
(106). PIP3 has been shown to activate protein kinase-C-^ in 
vitro, indicating a possible second messenger role for PIP3 
(107). PI 3'-kinase itself consists of an 85 kDa regulatory 
subunit (p85) and an 110 kDa catalytic subunit (pllO) (108-111). 
The regulatory subunit, p85, has been shown to have one Src 
homology 3 (SH3) domain and two Src homology 2 (SH2) domains 
(108-110); IRS-1 associates with PI 3'-kinase through the SH2 
domains of p85 and activation of the kinase takes place as a 
result (103,104). It has been reported that lRS-1 becomes 
serine phosphorylated by PI 3'-kinase during the interaction, 
but it is not clear what role, if any, this plays in the 
modulation of insulin signalling (112,113). 
Clues into the role(s) of PI 3'-kinase activation in 
insulin signalling have been obtained through the utilization of 
two structurally distinct PI 3'-kinase inhibitors, LY294002 and 
wortmannin. Wortmannin is an antifungal agent which inhibits PI 
3'-kinase in the nanomolar range (114,115), while LY294002 is a 
specific PI 3'-kinase inhibitor based on the bioflavonoid 
quercetin (116). In Swiss mouse 3T3 fibroblasts overexpressing 
human insulin receptors, LY294002 partially inhibited glucose 
uptake, amino acid uptake, and protein synthesis, while it 
completely inhibited DNA synthesis and p70 S6 kinase activation 
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(117). The use of wortmannin showed that the activation of PI 
3'-kinase during insulin stimulation is a pre-requisite for GLUT 
4 translocation and glucose uptake in CHO cells co-expressing 
human insulin receptors and GLUT 4 glucose transporters (118). 
These experiments indicate that activation of PI 3-'kinase is 
important for many aspects of insulin signalling. 
GRB-2; linking of p21£as to insulin signalling GRB-2 is 
a small molecular weight protein consisting entirely of one SH2 
domain and two SH3 domains, but no apparent catalytic domain 
(119). This "adaptor protein" binds IRS-1 at Tyr-895 after 
insulin stimulation (119-122). GRB-2 is thought to stimulate 
p2iras through interaction with one of its SH3 domains with a 
p2iras gdp/GTP exchange factor called mSOS (121-124). p21^®3 
activation results in the stimulation of the Ser/Thr 
phosphorylation cascade involving the mitogen-activated protein 
kinase (MAP kinase) pathway that ultimately leads to S6 kinase 
activation and cell proliferation (125). S6 kinase also appears 
to activate glycogen-associated protein phosphatase-1 (PPG-1) 
which then dephosphorylates glycogen synthase and phosphorylase 
kinase. This results in the activation of the synthase and 
inactivation of phosphorylase kinase, with the net effect being 
glycogen synthesis (126). Therefore, the interaction of 
tyrosine-phosphorylated IRS-1 with the GRB-2/mSOS complex may 
contribute to cell proliferation and glycogen synthesis. 
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SHPTP2 (Svp) SHPTP2, or Syp, is a protein tyrosine 
phosphatase containing two SH2 domains which binds to lRS-1 in 
response to insulin (101,127,128). SHPTP2 binding to the 
phosphorylated consensus motif of YVNI activates its phosphatase 
activity (129); therefore, binding of SHPTP2 to IRS-1 would 
presumably activate it in vivo. The downstream signalling of 
SHPTP2 remains to be elucidated, but SHPTP2 does appear to be a 
positive regulator of the MAP kinase pathway (130,131). 
Nek Nek is a 47 kDa adaptor protein composed of three 
SH3 domains and one SH2 domain (132), which recently has been 
shown to bind IRS-1 (133). It is phosphorylated on both serine 
and threonine residues in response to EGF, PDGF, phorbol esters 
and CAMP (134-136). However, Nek's role in insulin signalling 
is unclear. 
IRS-l-independent insulin signalling 
Shc/GRB-2/mSOS complex formation; insulin sensitive p21£g^ 
activation without IRS-1 She is another adaptor protein 
composed of a single SH2 domain, a glycine/proline rich collagen 
homology domain, and a unique N-terminal domain (137). She is 
tyrosine phosphorylated in response to insulin, which results in 
the formation of a Shc/GRB-2/mSOS complex (120,138,139). There 
is growing evidence that activation of p21^®® occurs primarily 
through the Shc/GRB-2/mSOS pathway, rather than the IRS-l/GRB-
2/mSOS pathway. First, in CHO cells expressing 
autophosphorylation-deficient insulin receptors, insulin 
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stimulated tyrosine phosphorylation on She, Shc/GRB-2 formation, 
and p21^®3 activation all still occur (140). Second, signalling 
through the interleukin (IL)-4 receptor, which results in the 
phosphorylation of lRS-1, but not She, fails to activate the MAP 
kinase pathway (141). Third, perhaps the most compelling 
evidence that activation of p21ras occurs via Shc/GRB-2/mSOS 
complex formation comes from mice with a targeted disruption in 
both copies of their lRS-1 genes ("IRS-1 knockouts") (142). In 
these mice, the insulin-induced activation of the MAP kinase 
pathway is observed, although IRS-1 is not present. The MAP 
kinase pathway is probably activated through She, since She is 
normally tyrosine phosphorylated in the mutant mice in response 
to insulin (142). 
"IRS-2" Another group who has described IRS-1 knockout 
mice has also found evidence for a putative "IRS-2". Araki et 
al. (143) observed a tyrosine phosphorylated protein -10 kDa 
above the position of IRS-1 which immunoprecipitated with PI­
S' kinase in mutant mice with no lRS-1. This protein, which does 
not blot or iinmunoprecipitate with antibodies against IRS-1, has 
been named "IRS-2". IRS-2 may act as an alternate substrate of 
the insulin receptor and may substitute for IRS-1 in binding to 
and activating PI 3'-kinase, since insulin-stimulated PI 3'-
kinase activation was observed in mutant mice and the IRS-2 
protein immunoprecipitated down with PI-3'kinase. Future 
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research in insulin signalling most certainly will include 
characterization of the lRS-2. 
Role of PTPases in insulin signal transduction 
General evidence for role(s^ of PTPases in insulin 
signalling There is substantial evidence supporting a 
role(s) for protein tyrosine phosphatases (PTPases) in insulin 
signalling; however, specific roles for specific phosphatases 
have not yet been confirmed. Microinjection of FTP-IB into 
Xenopus oocytes blocks insulin-stimulated S6 peptide 
phosphorylation and retards insulin-induced oocyte maturation 
(144,145), but it is not certain at what point(s) in the insulin 
signalling pathway the phosphatase is having the observed effect 
in this system. IRS-1 is phosphorylated by the activated 
receptor within seconds of insulin stimulation, but this 
phosphorylation is transient (146,147). The subsequent 
dephosphorylation of lRS-1 occurs despite continued insulin 
stimulation (147). Nothing is known about the specific 
PTPase(s) involved in this process. 
More is known about the roles that PTPases play in 
dephosphorylating the insulin receptor itself. In cultured 
cells and permeabilized adipocytes, dissociation of insulin from 
its receptor is followed by a rapid dephosphorylation of the 
receptor p-subunit and deactivation of the kinase (148-150). 
Additionally, vanadate and other related compounds which are 
known to inhibit PTPases enhance the phosphorylation state of 
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the insulin receptor and certain cellular substrate proteins, 
resulting in increased insulin signalling (151-154). These data 
suggest that PTPases which dephosphorylate the 
autophosphorylated insulin receptor may act to attenuate the 
insulin signal in vivo. 
Possible PTPase candidates for the dephosphorvlation of 
insulin receptor kinse in vivo Known PTPases seem to fall in 
to two broad categories, the receptor-type and non-receptor 
type. The receptor-type PTPases are composed of a glycosylated 
extracellular domain, a single transmembrane region, and one or 
two conserved catalytic domains (155,156). Examples of this 
type of PTPase are LAR (157,158), CD45 or LCA (158,159), and LRP 
(160). The non-receptor type has no extracellular or 
transmembrane domains, but typically a single catalytic region 
with additional domains with other functional properties (156). 
Examples of the non-receptor type PTPases are PTP-lB (161,162) 
and the T-cell PTPase (163). 
Clues into which PTPases may act to attenuate the insulin 
signal come from studies of the phosphorylation state of the 
kinase region of the insulin receptor kinase. 
Autophosphorylation of all three tyrosines in the kinase domain 
(Tyr-1146, 1150, and 1151) is required for full activation of 
phosphotransferase activity in an in vitro insulin receptor 
kinase assay (164,165). However, the receptor is frequently 
isolated from insulin-stimulated cells in the mono- or bis-
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phosphorylated form, suggesting that receptor 
autophosphorylation is closely regulated by phosphatases in vivo 
(165,166). Additionally, the initial dephosphorylation of the 
tris-phosphorylated form of the receptor kinase on either Tyr-
1150 or Tyr-1151 correlates with the deactivation of kinase 
activity (167). Therefore, studies were undertaken to determine 
which PTPases would preferentially dephosphorylate these 
tyrosines in the autophosphorylation domain of the insulin 
receptor. 
In vitro, PTPase will dephosphorylate a number of protein 
and peptide substrates, although with different kinetic 
parameters (155,159,160,163,168). Purified PTP-lB and CD45 are 
active against the autophosphorylated insulin receptor in vitro 
(158,159,162,169), while the catalytic domains of PTP-lB, LAR, 
and LRP expressed in recombinant bacterial systems are also 
active against the receptor in vitro (170,171). However, 
differences in dephosphorylation kinetics and regiospecificity 
exist among these phosphatases. For example, PTP-lB 
dephosphorylates Tyr-1150 on the tris-phosphorylated insulin 
receptor 4 times faster than the mono- or bis-phosphorylated 
receptor (169). In another study which utilized an insulin 
receptor related phosphopeptide corresponding to the 
autophosphorylated kinase domain, the authors observed 
preferential dephosphorylation of the three phosphotyrosines 
(172). In that study, PTP-lB preferentially dephosphorylated 
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Tyr-1150 or Tyr-1151, LAJR and CD45 preferred Tyr-1146, while the 
T-cell PTPases exhibited no specificity for a particular 
phosphotyrosine. 
Although Ramachandran et al. showed that LAR preferentially 
dephosphorylated Tyr-1146 on a tris-phosphorylated kinase domain 
peptide, other studies suggest that LAR actually preferentially 
dephosphorylates Tyr-1150 in intact insulin receptor (171) and 
may be important in attenuating insulin receptor kinase activity 
(173). Hashimoto et al. (171) observed the deactivation of the 
insulin receptor by LAR, LRP, and PTP-lB. LAR deactivated the 
receptor kinase two to three times more rapidly than LRP or PTP-
lB, and the tryptic map of the receptor p-subunit after 
dephosphorylation by LAR showed preferential dephosphorylation 
of Tyr-1150. Additional evidence that LAR may be involved in 
the modulation of insulin signalling in intact cells comes from 
a rat hepatoma cell line that had been made to express LAR 
antisense RNA (173). In these cells, LAR protein levels were 
suppressed by 63%, which increased insulin-dependent 
autophosphorylation of the insulin receptor by 150%, and, in 
turn, insulin-dependent PI 3'-kinase by 350%. Since LAR is 
prominently expressed in rat liver (174), it is a strong 
candidate for being a PTPase that may be involved in insulin 
signalling. 
Another strong candidate PTPase which may be involved in 
dephosphorylation of the insulin receptor in vivo is PTP-lB. As 
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mentioned before, PTP-lB activity against a phosphopeptide 
encompassing the autophosphorylation domain of the insulin 
receptor p-subunit results in the preferential dephosphorylation 
of Tyr-1150 or Tyr-1151 (172), sites critical for deactivation 
of the receptor kinase (167). When PTP-IB and insulin receptors 
were co-expressed to high levels, insulin receptor 
autophosphorylation was inhibited (175). Even PTP-lB mRNA 
levels are responsive to insulin. Treatment of rat hematoma 
cells with 100 nM insulin increases the abundance of the two 
mRNA's encoding PTP-lB by 1.6- and 3.1-fold, with no significant 
effect on the abundance of mRNA encoding LAR or LRP (174). 
Therefore, PTP-lB may provide feedback regulation of insulin 
signalling. Future research concerning the roles of PTPases in 
insulin signalling in vivo most certainly will involve further 
characterization of PTP-lB and LAR in this pathway. 
Diabetes and PTPase activity Severe obesity or non-
insulin dependent diabetes mellitus (NIDDM) is characterized by 
the diminished ability of insulin-dependent tissues to respond 
to insulin (176). This insulin-resistance could be the result 
of a number of defects in the insulin signalling pathway (177-
181). However, much focus has been put on evidence that insulin 
receptor kinase autophosphorylation and subsequent IRS-1 
phosphorylation are markedly decreased in insulin-responsive 
tissues of subjects with severe obesity or NIDDM (182-184), 
Recently, Nadiv et al. (185) have shown that this decreased 
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degree of phosphorylation of the insulin receptor may be due to 
the action of protein tyrosine phosphatases. The authors 
observed elevated cytosolic PTPase activity directed against the 
p-subunit of the insulin receptor in aged, insulin-resistant 
rats. Begum et al. (186) also reported increased PTPase 
activity toward intact insulin receptors in diabetic rat 
adipocytes, although they found the elevated PTPase activity in 
the particulate fraction. Regardless of the subcellular 
localization of the PTPases involved, enhancement of PTPase 
activity toward the insulin receptor kinase in insulin-dependent 
tissues would apparently result in impaired insulin receptor 
signalling in those tissues. 
The development of oral anti-diabetic agents which enhance 
insulin sensitivity in insulin-dependent tissues has received 
much attention (187-189). One anti-diabetic agent, 
pioglitazone, has been shown to increase insulin sensitivity 
through its ability to reactivate insulin receptor kinase 
autophosphorylation (190,191). Pioglitazone does not act 
directly on the receptor, since incubation of insulin receptors 
and pioglitazone in vitro does not result in increased receptor 
kinase autophosphorylation (190). There is now strong evidence 
that this indirect effect of pioglitazone on receptor 
autophosphorylation is due, at least in part, to normalization 
of elevated PTPase activities in insulin-unresponsive cells 
(192). In this study. Rat 1 fibroblasts overexpressing the 
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human insulin receptor were made impaired in insulin signalling 
with treatment with high glucose; decreased phosphorylation of 
the insulin receptor and lRS-1, along with elevated PTPase 
activity, were associated with the impaired signalling. 
Pioglitazone treatment reversed all these defects in insulin 
signalling, apparently through decreasing the activity of the 
elevated cytosolic PTPase activities. Preliminary evidence 
suggests that the cytosolic PTPase responsible for those effects 
is PTP-lB (192). Therefore, some anti-diabetic agents may act 
to decrease elevated PTPase activities in insulin-dependent 
tissues, restoring insulin sensitivity to those tissues by 
allowing autophosphorylation of the insulin receptor and 
resultant insulin signal transduction. 
Nutrition, glucose tolerance, and insulin signalling 
In 1959, chromium was shown to be required for maintaining 
normal glucose tolerance in rats (193). This lead to the notion 
that a slight chromium defiency in humans could mean an 
increased risk of developing diabetes (194). Evidence to 
support this hypothesis came from two double-blind, crossover 
studies in humans, where increased glucose tolerance was 
observed upon chromium supplementation of subjects with mildly 
impaired glucose tolerance (195,196). 
There is mounting evidence that the chromium responsible 
for improved glucose tolerance is not that of a simple inorganic 
chromium, such as chromium chloride, but that the chromium must 
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be complexed with certain ligands to exert its biological 
activity (194,197,198). There are two known biological chromium 
complexes which have received much attention. The first, termed 
glucose tolerance factor (GTF), was originally extracted from 
Brewer's yeast and was found to contain chromium, nicotinic 
acid, glycine, glutamic acid, and cysteine (199). A synthetic 
mixture of the components of GTF is nearly identical to Brewer's 
yeast GTF in its physical characteristics and biological 
activity (199). Furthermore, the synthetic mixture mimicks the 
effects of extracted GTF by lowering plasma glucose 
concentrations in genetically diabetic mice (198). The second 
biologically active chromium complex is known as low-molecular 
weight chromium binding ligand (LMWCr), which has been isolated 
from bovine colostrum (200). Having a molecular weight of 
-1500, LMWCr contains chromium, aspartic acid, glutamic acid, 
and cysteine, but no nicotinic acid. LMWCr has been shown to 
exhibit biological activity, as detected by glucose oxidation in 
isolated fat cells, similarly to that of GTF (200). 
Some extracts of certain spices also exhibit insulin 
potentiating activity in the rat epididymal fat cell assay 
(201,202). One of the spices which best potentiates insulin's 
effects in these cells is cinnamon (201). It is not known how 
cinnamon exerts its effect. It apparently is not due to the 
action of biological chromium in the spice, since chromium 
concentration in spices is not correlated with their insulin 
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potentiating activity (201). A number of phenols, aldehydes, 
and acids have been identified in extracts of cinnamon, 
including eugenol, cinnamaldehyde, and cinnamic acid (203). It 
remains to be seen if any of these identified compounds are 
responsible for cinnamon's biological activity, or if a 
previously unidentified compound is responsible. 
Dissertation organization 
This disseration consists of three papers which follow the 
general introduction. The first paper was published in the 
Archives of Biochemistry and Biophysics and describes the role 
of arginine residues in the interaction between calcineurin and 
calmodulin. The second paper is to be submitted for publication 
and is a continuation of studies in the first paper, describing 
the role(s) of arginine in the regulatory domains in 
calcineurin. The third paper is to be submitted for publication 
and deals with the regulation of another phosphatase, protein 
tyrosine phosphatase-1 (PTP-1), by compounds derived from 
cinnamon. The general summary and discussion follov/s the third 
paper, while the references cited in the general introduction 
and general summary follow the general summary. 
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Abbreviations 
CaN, calcineurin; 
CaM, calmodulin; 
EGTA, Ethylene glycol bis(J3-ainino ethyl ether)N,N'-tetraacetate; 
pNPP, para-Nitrophenyl Phosphate; 
pNP, para-Nitrophenol; 
MOPS, 3-(N-inorpholino)propanesulfonic acid; 
PVDF, polyvinylidene difluoride; 
HRP, horseradish peroxidase; 
SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis; 
smMLCK, smooth muscle myosin light chain kinase 
Abstract 
We have used an enzyme, peptidylarginine deiminase, to 
convert certain arginyl groups in calcineurin to citrulline. 
Amino acid analysis shows that only 3 out of 34 arginines in 
calcineurin were deiminated; citrulline seems to be localized 
only in the calcineurin A (CaN A) subunit. Upon incubation with 
deiminase, the Mn^+Zcalmodulin stimulated phosphatase activity 
decreases to 20-40% of the original activity within one hour. 
However, the reduction in enzyme activity is fully protected by 
addition of calmodulin to the deimination reaction, and only 1.5 
mol citrulline/mol calcineurin is found in this case. Removal 
of the calmodulin binding domain of the deiminated CaN A by 
limited proteolysis results in the reactivation of the 
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phosphatase to the same level as digested native calcineurin and 
also results in the loss of all citrulline residues. The 
calmodulin activation curve of the deiminated enzyme is 
significantly shifted; the calculated apparent Kact using native 
calmodulin is 15-fold higher than that of native calcineurin 
while the apparent Kact using a fluorescent derivative of 
calmodulin, dansyl-calmodulin, is 10-fold higher. However, the 
Vm of deiminated calcineurin is similar to that of native, if 
highly elevated levels of calmodulin are used to activate the 
modified calcineurin. To determine directly if the binding of 
calmodulin to calcineurin is affected upon deimination, 
fluorescence titrations using dansyl-calmodulin were performed. 
The Kd of deiminated calcineurin determined from these 
titrations is 10-fold higher than that of unmodified 
calcineurin, indicating that calmodulin binding is indeed 
affected. These data indicate that at least one arginine is 
important for calmodulin binding and is likely located at the 
calmodulin binding site of the CaN A subunit. 
Introduction 
Calcineurin (CaN)^ is a major soluble calcium and 
calmodulin binding protein found in brain extracts (1,2). First 
identified as an inhibitor of calmodulin-stimulated cyclic 
nucleotide phosphodiesterase because it competed for calmodulin 
binding (2-4), calcineurin was later shown to have Ca^+ZcaM 
regulated phosphatase activity (5,6). This activity has been 
shown to be inhibited by a complex of the immunosuppressant 
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drugs cyclosporin A or FK506 and their respective intracellular 
receptors (7-9). A heterodimeric enzyme, calcineurin is 
comprised of a 1:1 complex of a large subunit, CaN A, Mr 58-61 
kDa, and a small subunit, CaN B, Mr 15-19 kDa (2,10,11). CaN A 
contains the catalytic site (12) and sole calmodulin binding 
domain (1) whereas CaN B has 35% sequence identity to calmodulin 
(13) and binds 4 calcium ions with micromolar affinity (1). 
Recently shown to have highly homologous secondary structure to 
calmodulin (14), CaN B is thought to play a regulatory role in 
conferring additional calcium sensitivity to the enzyme in vivo 
(15). 
Limited proteolysis of calcineurin by certain proteases has 
facilitated the domain mapping of CaN A, while CaN B seems 
resistant to the proteolytic enzymes utilized (16-19). In these 
experiments, it was shown that the CaN A subunit contains 
distinct CaN B-binding, CaM-binding, and autoinhibitory domains. 
The CaN B-binding domain is located on a 44 kDa N-terminal 
catalytic core, whereas the CaM-binding and autoinhibitory 
domains are found on a 14 kDa C-terminal fragment (19). The 
CaM-binding and autoinhibitory domains have also been confirmed 
using sequence homology for the CaM-binding domain (20) and 
peptide inhibition studies for the autoinhibitory domain (21). 
The 44 kDa proteolytic fragment is catalytically active but is 
insensitive to activation by Ca^+ZCaM (16-19). 
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Chemical modification of arginyl residues by phenylglyoxal 
has provided limited knowledge of the role(s) arginine plays in 
calcineurin function (22). A time and concentration dependent 
inactivation of calcineurin activity is seen when calcineurin is 
reacted with phenylglyoxal. The enzyme is protected from 
phenylglyoxal inactivation partially by ADP, a competitive 
inhibitor of calcineurin, and completely by pNPP, a substrate of 
the phosphatase. This suggests that arginine(s) are important 
for catalytic activity in or near the catalytic site of the 
enzyme. Kinetic analysis of the order of the inactivation 
reaction indicates that only one modified arginine may be 
responsible for the observed loss of activity. However, 
inactivation of calcineurin with radioactively labeled 
phenylglyoxal results in incorporation of 12 equivalents of 
phenylglyoxal, making identification of the relevant arginine 
difficult (22). 
Peptidylarginine deiminase has been used to enzymatically 
convert arginine residues in proteins and peptides to citrullina 
(23,24). Citrulline is formed from arginine by the loss of a 
single amino group at the end of the side chain, which results 
in the loss of the positive charge but does not drastically 
alter the structure of the side chain. Because a bulky group, 
such as phenylglyoxal, is not introduced into the modified 
protein, effects due to steric hindrance of the modified group 
on the protein can be discounted. Therefore, peptidylarginine 
deiminase is a useful probe to study the role of the positive 
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charge of arginine's guanidino group by conversion of it to a 
neutral amino acid which cannot be introduced into proteins by 
simple site-directed mutagenesis. The present paper deals with 
the study of a modified form of bovine brain calcineurin in 
which certain arginyl groups have been converted to citrulline 
by the deiminase, resulting in a marked reduction in the 
enzyme's phosphatase activity and binding affinity for 
calmodulin. We find evidence suggesting that modification of an 
arginine residue(s) localized in the calmodulin binding site is 
responsible for these observations; therefore, this approach may 
prove useful to further characterize calcineurin-calmodulin 
interaction. 
Experimental Procedures 
Materials All buffers, as well as pNPP, EGTA, and 
phenyl-Sepharose, were purchased from Sigma. All other 
chemicals were from Fisher. PVDF membrane and HRP-conjugated 
goat anti-rabbit IgG were from BioRad. Antibody recognizing 
modified citrulline residues in proteins has been described 
previously (25). ECL chemiluminescent reagents were purchased 
from Amersham (Arlington Heights, IL). 3,3'-diaminobenzidine 
tetrahydrochloride (DAB) was from Gibco BRL. 
Enzymes Calcineurin was purified from bovine brain by 
minor modification of the method of Sharma et al. (26). 
Calmodulin was also from bovine brain using the method of Sharma 
and Wang (27) modified to include phenyl-Sepharose 
chromatography after DE-52 chromatography, according to 
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Gopolakushna and Anderson (28). Peptidylarginine deiminase was 
purified from frozen rabbit skeletal muscle, according to 
Takahara et al. (29). Clostripain was purchased from Sigma. 
Protein concentration was determined by the method of Bradford 
(30). 
Calcineurin assays Using pNPP as substrate, calcineurin 
was assayed continuously by measuring the pNP at 410 nm in a 
Beckman DU-7 spectrophotometer. Temperature was maintained at 
30°C using a Peltier temperature control element. Typical 
assays were done in 25 mM MOPS, pH 7.0, 1 mM MnCl2 or 0-5 mM 
NiCl2, 20 mM pNPP, 10 ng/ml calmodulin, and 10 jxg/ml 
calcineurin. The concentrations of metal ion used in each case 
were determined to be saturating (data not shown). 
Sodium Dodecvl Sulfate-Polvacrvlamide Gel Electrophoresis, 
Electroblotting. and Western Analysis for Citrulline 
Calcineurin samples were separated by SDS-PAGE (31) on a 12.5% 
polyacrylamide gel and electroblotted onto PVDF using 10 mM 
CAPS, pH 11.0, in 10% methanol or onto nitrocellulose using 25 
mM Tris, pH 8.3, and 192 mM glycine in 20% methanol (constant 
300 mA for 1 hour). The membrane was either stained for protein 
with 0.025% (w/v) Coomassie Brilliant Blue R250 in 50% methanol 
(v/v) or processed for western analysis using an anti-modified-
citrulline antibody (25). Before western analysis, the blotted 
membrane was incubated at 37°c in modification medium (1 yol 
ddH20, 1 vol 2% diacetyl monoxime/1% antipyrine/1 N acetic acid, 
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and 2 vol 85%(w/w)H3P04/98%(w/w)H2S04/H20 (20/25/55, v/v)) to 
modify citrulline residues. After rinsing with ddH20, the 
membrane was soaked in blocking medium (5% skim milk in 10 mM 
Tris-HCl, pH 7.5, 0.14 M NaCl, 0.1% Tween 20 (TBST)) for 1 hour, 
then the antibody (0.125 ng/ml) was added and the blot incubated 
for 2 more hours. The membrane was washed with 3 X 10 min with 
TBST, soaked in blocking medium for 30 min, and soaked in HRP-
goat anti-rabbit igG (1:4000) for 1 hour. After washing with 
TBST as before, detection was performed either by addition of 
DAB/H2O2 to the blot or according to the ECL protocol of 
Amersham. 
Amino Acid Analysis Protein bands (CaN A and CaN B) 
separated by SDS-PAGE and electroblotted onto PVDF were excised 
from the membrane and subjected to amino acid analysis. The 
analysis was performed on an Applied Biosystems 42OA Amino Acid 
Analyzer by the Iowa State University Protein Facility. 
Quantitation of citrulline was determined from the citrulline 
plus ornithine peaks in the HPLC trace, because degradation of 
citrulline into ornithine occurs during the acid hydrolysis step 
(23). 
Fluorescence Measurements and Kh Calculations Dansyl-
CaM, with an incorporation of 1 mol dye/mol CaM, was prepared as 
described by Kincaid et al. (32). The buffer used for the 
fluorescence experiments was 25 mM MOPS, pH 7.0, containing 1 mM 
MnCl2. Fluorescence emission spectra and titration of dansyl-
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CaM and calcineurin were done at an excitation wavelength of 340 
nm using a SPEX fluorolog 2 spectrophotometer. For titration 
experiments, total fluorescence intensity was measured at an 
emission wavelength of 500 nm. Fluorescence data were obtained 
60 seconds after addition of titrant, of which concentrated 
solutions were added to keep dilution below 5%. Intensity data 
were corrected for dilution and background fluorescence of 
protein and solvent. 
Kd of CaN-CaM was calculated from total fluorescence data 
using the method of Malencik and Anderson (33). By measuring 
the fluorescence intensity of fully bound (Fco) and unbound (Fo) 
ligand (dansyl-CaM), and then measuring fluorescence intensity 
values during titration (F), a fractional saturation (<i>) of 
dansyl-CaM can be calculated for each titration point; 
<t> = (F/Fo-l)/(Foo/Fo-l) 
Knowing <l>, [CaN]free can be calculated. A hyperbolic plot of 
F/Fo vs. [CaN]free "then was done using Enzfitter by Elsevier-
Biosoft, and this yielded the calculated Kd-
Results 
Effect of deimination of calcineurin on phosphatase 
activity When calcineurin was incubated with 
peptidylarginine deiminase, the Mn^+ZcaM-stimulated enzymatic 
activity of calcineurin was reduced to 20-40% of the original 
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activity within one hour (Fig. 1). Further incubation of 
calcineurin with deiminase resulted in no additional loss of 
activity (data not shown). Addition of calmodulin to the 
reaction mixture before addition of deiminase, however, fully 
prevented the decrease in calcineurin activity (Fig. 2A). This 
observed effect could be due to calmodulin protecting 
calcineurin from modification(s) introduced directly into 
calcineurin by the deiminase, but it also could be due to 
interference of calcineurin deimination by preferential 
deimination of calmodulin. To distinguish between these two 
possibilities, calmodulin preincubated with the deiminase was 
used in a standard calcineurin assay to determine its ability to 
activate calcineurin. As seen in Figure 2B, preincubation with 
deiminase had no effect on calmodulin's ability to activate 
calcineurin. Additionally, we found no evidence that calmodulin 
was a substrate for the deiminase, as determined by western 
analysis (described later in Fig. 3A, lane 4). These data 
indicate that calmodulin probably protected calcineurin by 
forming a complex with it and preventing a certain 
modification(s) by the deiminase. 
Localization of citrulline residues in calcineurin The 
above calmodulin protection result suggested that one or more 
arginines important for calmodulin binding or activation were 
modified by the deiminase. The localization of converted 
arginines in modified calcineurin has been facilitated by 
Figure 1. Time course of incubation of calcineurin with 
deiminase. Control CaN (D) and CaN + deiminase 
(•) were incubated at 37°C in a buffer containing 
50 mM Hepes, pH 7.2, 5 mM CaCl2, 5 mM DTT with or 
without 80 jjq/ml deiminase, then aliquots were 
removed and assayed immediately at the designated 
time points. Calcineurin concentration for the 
deimination reaction was 1.1 mg/ml. 
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Figure 2. Calmodulin protection of the reduction in 
phosphatase activity of calcineurin during 
incubation with peptidylarginine deiminase. (A) 
Reaction was performed as in Figure 1, except that 
calmodulin (42 jjM, 3-fold molar excess over 
calcineurin) was included in the deimination 
reaction. Control CaN (•), CaN + deiminase (•), 
control CaN + CaM (A), and CaN + deiminase + CaM 
(X). Enzyme velocities were normalized to 100 % 
based on the velocity of the first assay point at 
time 0; actual velocities in pmol/min/mg were: 
control CaN, 2.4, CaN + deiminase, 2.8, CaN + CaM, 
2.1, and CaN + deiminase + CaM, 2.3. (B) 42 ^M 
calmodulin was incubated at 37°C in the absence 
(•) or presence (O) of 80 ;jg/ml deiminase. Then, 
the calmodulin was used in a standard CaN assay 
(see Experimental Procedures) at the times 
indicated to determine its ability to activate 
calcineurin. 
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(figure 2 continued) 
Figure 3. Localization of citrulline residues in calcineurin. 
(A) Reactions were performed as in Figure 2, then 
5 ]jg CaN per lane was loaded onto a 12.5% SDS-PAGE 
gel. After electrophoresis, the separated 
subunits were electroblotted onto PVDF and 
analyzed for the presence of citrulline using an 
anti-citrulline antibody (see Experimental 
Procedures). Lanes are: (1) Control CaN (2) 
Control CaN + CaM (3) CaN + deiminase (4) CaN + 
deiminase + CaM. Lanes 5 and 6 are Control CaN 
(5) and CaN + deiminase (6) to which 2 U of 
clostripain performed as in (A), then 5 pg CaN per 
lane was loaded onto a 12.5% SDS-PAGE gel. (B) 
After electrophoresis, the gel was stained with 
Coomassie blue. Lanes are; (1) molecular weight 
markers, 97, 66, 45, 31, 22, and 14 kDa (2) 
undigested CaN (3) digested CaN. Proteolysis 
results in the formation of a 45 kDa N-terminal 
CaN A fragment with no calmodulin binding domain 
(19). 
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electroblotting separated samples on an SDS-PAGE gel onto PVDF 
followed by western analysis using an anti-modified-citrulline 
antibody (25). The western analysis revealed that only the CaN 
A subunit contained citrulline (Fig. 3A), even after detection 
with the extremely sensitive chemilluminescent ECL (Amersham) 
technique and overexposure of the film (data not shown). 
Peptides of molecular weight lower than 61 kDa, but higher than 
that of calmodulin, were found to contain citrulline (Fig. 3A, 
lanes 3 and 4); these are presumably degradation products 
generated during the preparation of calcineurin. Since the 
deiminase was found to deiminate itself (not shown), an accurate 
determination of the incorporation of citrulline into 
calcineurin was carried out by amino acid analysis on the CaN A 
and CaN B bands separated from the deiminase by SDS-PAGE and 
electroblotted onto PVDF. Two independent determinations 
yielded 2.6 and 3.3 mol citrulline/ mol CaN A subunit. 
Therefore, approximately 3 arginine residues are modified by the 
deiminase out of a possible 28 arginines in the catalytic 
subunit. 
Hubbard and Klee have shown that limited digestion of 
calcineurin by clostripain results in the formation of a 44 kDa 
N-terminal catalytic domain of CaN A which has CaM-independent 
phosphatase activity, while the CaN B subunit is not cleaved 
(19). Upon proteolysis, they observed Ca^+ZCaM-independent 
phosphatase activity 3-fold higher than that of native CaM-
dependent activity, because the 14 kDa C-terminal region of CaN 
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A cleaved from the N-terminal 44 kDa fragment contains both the 
calmodulin binding and autoinhibitory domains. To determine if 
any or all of the modified residues in deiminated CaN A were in 
the C-terminal region, we performed a limited proteolysis of 
deiminated calcineurin by clostripain (34,35). This yielded a 
44 kDa N-terminal fragment (Fig. 3B) in which no citrulline was 
detected either by western (Fig. 3A, lane 6) or amino acid 
analysis. A citrulline positive 14 kDa fragment was not seen on 
the gel, since the fragment is further proteolyzed once cleaved 
from the intact protein (19). When the CaM-independent activity 
of the 44 kDa catalytic fragment was measured, the deiminated 
calcineurin digest showed comparable activity to that of the 
unmodified calcineurin digest. (Fig. 4). Therefore, the loss of 
citrulline and the calmodulin binding domain from the 44 kDa 
fragment upon limited proteolysis is accompanied by reactivation 
of deiminated phosphatase activity. As observed by Hubbard and 
Klee, 3-fold activation of native CaM-dependent activity is seen 
(Fig. 4) because the proteolysis results in the cleavage of the 
autoinhibitory domain as well as the CaM binding domain (19,21). 
An interesting observation is that, although addition of 
calmodulin to the deimination reaction prevented loss of the 
CaM-dependent phosphatase activity of calcineurin, the western 
analysis showed deimination of CaN A without detectable 
deimination of calmodulin (Fig. 3, lane 4). Amino acid analysis 
of calcineurin A obtained after preincubation with calmodulin 
and the deiminase gave 1.4 and 1.7 mol citrulline/mol in two 
Figure 4. Reactivation of deiminated calcineurin upon limited 
proteolysis with clostripain. 5.2 U of 
clostripain was added to 21 ng unmodified or 
deiminated calcineurin and allowed to react 10 
seconds. Digested control and deiminated 
calcineurin was assayed in the presence or absence 
of calmodulin. (Closed bars, unmodified CaN, open 
bars, deiminated calcineurin). 
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before proteolysis after proteolysis 
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independent determinations. This indicates that one or two of 
the modifications taking place during the deimination reaction 
are irrelevant to the loss of activity seen when calmodulin is 
not included in the reaction. Therefore, deimination of only 
one or possibly two of the three modified arginine residues in 
CaN A may be necessary for the loss of calcineurin activity upon 
its deimination in the absence of calmodulin. An alternative 
explanation is that more than two arginines are partly modified, 
and all of these changes contribute to the inactivation. 
Kinetic and activation constants Using a range of 8-80 
mM of the substrate pNPP and a constant concentration (10 ^ g/ml) 
of calmodulin, native calcineurin exhibited a Km of 30.2 mM and 
a Vm of 2.56 /imol Pi/min/mg (Table I). After modification with 
deiminase, the for pNPP was relatively unchanged (38.9 mM), 
while the Vn, was half the value (0.96 pmol Pi/min/mg). However, 
when the phosphatase activity of unmodified and modified 
calcineurin was measured using increasing concentrations of 
calmodulin at constant pNPP, the deiminated calcineurin showed a 
similar maximum velocity as that of native, if high enough 
concentrations of calmodulin were used to activate the 
deiminated calcineurin (closed circles of Fig. 5). Indeed, the 
Vm of deiminated calcineurin was measured to be similar to that 
of native, if saturating calmodulin was used to activate each 
form of calcineurin (Table I). Still, the calculated apparent 
Kact of deiminated calcineurin by calmodulin was 15-fold higher 
than the apparent Kact of native (Table II), indicating that 
Table I. Kinetic parameters of calcineurin after deimination. Notes. Control or 
deiminated calcineurin was assayed (A) with a constant 10 iiq/ml calmodulin and a 
range of 8-80 mM pNPP or (B) saturating calmodulin conditions for CaN (20 pg/ml 
CaM) and deiminated CaN (500 iig/ml CaM) with a range of 8-200 mM pNPP. 
Saturating calmodulin conditions for control and deiminated calcineurin were 
determined from Figure 5; these concentrations of calmodulin activated both of 
these forms of the enzyme with a similar velocity of reaction using pNPP. Vn, 
differs between (A) and (B) for control CaN because these determinations were 
made using two different preparations of CaN. Kinetic parameters and errors 
were determined with Enzfitter computer software by Elsevier-Biosoft. 
Kni_lnm Vm (nmol Pi/min/mq) 
A. 10 uci/ml CaM 
CaN 
CaN + deiminase 
30.2 ± 2.0 
38.9 ± 10.2 
2.56 + 0.07 
0.96 ± 0.12 
B. saturating CaM 
CaN 
CaN + deiminase 
38.4 + 4.1 
8 2 . 0  ±  1 2 . 2  
1.36 + 0.07 
1 . 1 6  ±  0 . 0 8  
Figure 5. Activation curves of native and deiminated 
calcineurin with native and dansyl-calmodulin. 
Calcineurin preincubated at 37°C for 1 hour 
without or with deiminase was checked for 
reduction in activity, then placed on ice. 
Aliquots were then taken and assayed for activity 
using increasing concentrations of calmodulin or 
dansyl-calmodulin. (CaN + CaM (B); CaN + dansyl-
CaM (A); deiminated CaN + CaM (•); deiminated CaN 
+ dansyl-CaM (*)). 
51 
100 
90-
80-
70-
50-
40-
30-
20 
1 2 3 4 5 
log [CaM], nM 
Table II. Activation and dissociation constants of control and deiminated calcineurin 
with calmodulin. Notes. Activation (Kgct) and dissociation (Kd) constants were 
determined from the data in Figures 5 and 6 using the Enzfitter computer software by 
Elsevier-Biosoft. The apparent Kact of CaN by CaM was calculated without correction 
for CaN concentration to facilitate comparison of the value obtained with those found 
in the literature, which were calculated similarly. The apparent Kact obtained for 
control CaN obtained in this study (37 nM) agrees well with the range of values found 
in the literature (16-100 nM, references 11, 53-56). Although methodology differs 
greatly for Kd determinations, the Kd obtained in this study (5.5 nM) also agrees with 
values found in the literature (0.2-8.0 nM, references 2,57,58). 
Kact_JnMl KH (nM) 
CaM dansyl-CaM dansvl-CaM 
CaN 37 ± 7 34 ± 10 5.5 ± 1.6 
CaN + deiminase 657 ± 240 325 + 120 55.6 + 15.7 
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extremely high concentrations of calmodulin were needed to 
activate deiminated calcineurin. 
Binding constants Since calmodulin's ability to 
activate calcineurin decreased upon deimination of calcineurin, 
it was necessary to know whether the problem lay in calmodulin's 
activation of calcineurin or in the binding of calmodulin to 
calcineurin. To distinguish between these two possibilities, a 
fluorescent derivative of calmodulin, dimethylaminonaphthalene 
(dansyl)-calmodulin, was employed. Dansyl-calmodulin undergoes 
a Ca2+-dependent increase in fluorescence intensity which is 
enhanced when it binds calcineurin (36). By measuring the 
increase in fluorescence intensity during the dansyl-CaM-
calcineurin titration, the dissociation constant, Kd, can be 
found. 
To insure that dansyl-calmodulin could bind to calcineurin 
similarly to native calmodulin, its ability to activate 
calcineurin was measured. Although the maximal velocity of 
calcineurin activated by dansyl-calmodulin was only 60-70% of 
that of calcineurin activated by native calmodulin (Fig. 5), a 
comparison of the apparent Kact and Kd of native vs. deiminated 
calcineurin was desired. Dansyl-calmodulin activated 
calcineurin with a similar Kact to the non-fluorescent 
derivative (Fig. 5 and Table II), allowing such a comparison. A 
10-fold difference in the apparent Kact was observed between the 
native and deiminated forms of calcineurin when dansyl-
calmodulin was used as an activator (Table II). Similarly, a 
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10-fold difference in Kd for dansyl-calmodulin was found between 
native and deiminated calcineurin (Fig. 6 and Table II). This 
indicates that the deimination of calcineurin indeed affects 
binding of calmodulin to calcineurin and that the 10-fold 
difference in the apparent Kact between native and deiminated 
forms of calcineurin is likely due to a comparable decrease in 
calmodulin binding to calcineurin upon deimination. 
Metal ion dependency of deiminated calcineurin 
Calcineurin can be activated in vivo by a number of divalent 
metal ions, the most efficient among these being Mn^"*" and Ni2+ 
(37,38). As stated before, the loss of calcineurin's 
phosphatase activity upon deimination was seen when calcineurin 
was assayed in the presence of Mn2+ using pNPP as substrate. 
However, when Ni2+ (0.5 mM) was used to activate calcineurin 
which had been incubated with deiminase and shown to have 
reduced activity when assayed with 1 mM MnCl2 (control, 9.17 ± 
0.74 nmol Pi/min, vs. deiminated, 3.96 ± 0.23 nmol Pi/min), the 
loss of activity was not observed (control, 3.48 ± 1.06 nmol 
Pi/min, vs. deiminated, 3.67 ± 0.29 nmol Pi/min). The reason 
for this result is unclear at this point, but may be related to 
different conformations the Mn2+- and Ni2+-stimulated enzymes 
may undertake upon metal binding (39). Indeed, the observation 
that deimination of the C-terminus of CaN A affects Ni2+- and 
Mn2+-activated calcineurin differently is consistent with the 
report that the autoinhibitory domain of CaN A influences Ni2+ 
and Mn2+ activation of calcineurin differently (40). 
Figure 6. Fluorescence titrations of dansyl-calmodulin with 
calcineurin and deiminated calcineurin. Aliquots 
of control CaN (•) or deiminated CaN (•) were 
added to dansyl-calmodulin and increases in 
fluorescence intensity were measured 60 seconds 
after addition of titrant using a SPEX fluorolog 2 
spectrophotometer. Inset: Hyberbolic plot of 
fraction CaM bound vs. free CaN (nM), with 
theoretical curves, as detemiined by the Enzfitter 
software, superimposed upon the data. 
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Discussion 
We have generated a modified form of calcineurin containing 
three citrulline residues localized to the 14 kDa C-terminal 
region of the CaN A subunit, which has previously been shown to 
contain the calmodulin binding domain of calcineurin (19). 
Conversion of these arginines to citrulline results in an enzyme 
with a significantly lower binding affinity for calmodulin and 
reduced activity when assayed under subsaturating calmodulin 
conditions. However, conversion of all three modified arginines 
is probably not required for these observed effects since 
addition of calmodulin to the deimination reaction yields a 
deiminated enzyme which retains full activity. This enzyme only 
contains an average of 1.55 mol citrulline/ mol calcineurin; 
therefore, modification of only one or two of the three modified 
arginine residues in CaN A may be necessary for the loss of 
activity upon its deimination in the absence of calmodulin. 
Many studies on the interaction between calmodulin and the 
enzymes which it activates have focused on the role of 
hydrophobic residues either in the enzyme (41, reviewed in ref. 
42) or in CaM itself (43-46). X-ray crystal (43) and NMR 
solution (44) structures of calmodulin bound to a peptide of 
smooth muscle myosin light chain kinase (smMLCK) show that the 
binding of calmodulin to its target is probably dominated by van 
der Waals forces. However, the data presented in this paper 
show the importance of the positively charged side chain of 
arginine residues in calcineurin-calmodulin binding, since the 
58 
introduction of citrulline at these positions results in the 
loss of the positive charge but does not drastically alter the 
structure of the side chain. Although Meador et al. (43) 
observed that 80% of the contacts between calmodulin and the 
smMLCK peptide were of the van der Waals type, they also noted 
that all seven basic residues of the smMLCK peptide make salt 
bridges with CaM. 
The calmodulin-binding sequence in calcineurin is a 
predicted basic amphipathic a-helix which contains five 
arginines (20). Since one or two relevant arginine residues in 
the CaN A subunit were found to be modified by the deiminase, 
the modified residue(s) responsible for the loss of 
calcineurin's calmodulin binding may lie in this calmodulin 
binding sequence. Indeed, using both mutational and X-ray 
cirystallographic techniques (43,44,47-49), arginine residues 
have been shown to be important for many interactions between 
calmodulin and the calmodulin binding sequence from smooth 
muscle myosin light chain kinase (smMLCK),. a sequence with which 
calcineurin shows strong homology in its own calmodulin binding 
domain. Although the mechanism of activation differs between 
smMLCK and calcineurin (50-52), some similarities still may 
exist for calmodulin binding to the two enzymes, since this 
strong homology between them does occur. If this is the case, 
then modification of arginines in this region would surely 
disrupt calmodulin binding such as observed with the deimination 
of calcineurin. 
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Before more in depth analysis of the possible roles of 
arginines in the calmodulin binding domain of calcineurin is 
attempted, full characterization of the modified residues must 
be completed. The clostripain digestion conditions in this 
study favored complete digestion of the 14 kDa C-terminus of CaN 
A, leaving only a 44 kDa N-terminal fragment for analysis for 
citrulline. However, digestion conditions may be altered so 
that different defined derivatives of CaN A may be generated 
(19). In a preliminary experiment, we have altered the 
digestion conditions and generated a 45-46 kDa fragment of 
calcineurin (data not shown). This citrulline-containing 45-46 
kDa fragment may be the N-terminal catalytic fragment of CaN A 
plus some C-terminal residues, which would support the idea that 
one or two arginines in the CaM-binding domain of CaN A are 
being modified by the deiminase. Further characterization of 
this fragment is in progress. 
Contributions of authors: Tatsuo Senshu provided the anti-
modified citrulline antibody for the Western blots. All other 
experiments were conducted and the manuscript was written by 
Jennifer Imparl-Radosevich, under the direction of Donald 
Graves. 
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Abstract 
In this paper we describe the effects of converting certain 
arginine residues to citrulline on two recombinant calcineurins 
(CaN). The first is a full-length rat brain calcineurin, 
denoted CaNsoo/ and the second is a truncated calcineurin in 
which previously identified autoinhibitory sequences on the CaN 
A subunit have been deleted (denoted CaN457). Deimination of 
CaNsoo results in the conversion of approximately 4 arginines to 
citrulline and in the reduction of its phosphatase activity in 
our assay to 20-40% of its original activity within one hour. 
Including calmodulin in the deimination reaction protects CaNsoo 
from this loss of activity. Cleaving the C-terminal domain, 
where the calmodulin binding site of calcineurin is located, 
from deiminated CaNsoo reactivates the phosphatase activity to 
the level of digested control CaNsoo. All these observations 
had been described using bovine brain calcineurin and had been 
shown to be due to an apparent reduced affinity of calmodulin 
for deiminated calcineurin (24). On the other hand, deimination 
of truncated CaN457 results in the incorporation of 0.5 mol/mol 
less citrulline than CaNsoo and no loss of phosphatase activity. 
The reduced amount of citrulline in CaN4S7 could be due to 
truncation of an arginine which is normally deiminated on the 
full-length CaNsoo- Therefore, deimination of an arginine not 
present in the truncated CaN457 may be responsible for the 60-
80% loss of phosphatase activity and reduced calmodulin binding 
of deiminated full-length rat and bovine brain calcineurins. 
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Introduction 
Calcineurin, a calmodulin stimulated phosphatase (1,2), is 
a heterodimeric enzyme composed of a large subunit, CaN A, Mr 
58-61 3cDa, and a small subunit, CaN B, Mr 15-19 kDa (3-5). The 
phosphatase activity of calcineurin is inhibited by a complex of 
the immunosuppressant drugs cyclosporin A or FK506 and their 
respective intracellular receptors (6-8). The CaN A subunit 
contains the catalytic site (9) and sole calmodulin binding 
domain (10), whereas CaN B has 35% sequence identity to 
calmodulin (11) and binds four calcium ions with micromolar 
affinity (10). Recently shown to have highly homologous 
secondary structure to calmodulin (12), CaN B is thought to play 
a regulatory role in conferring additional calcium sensitivity 
to the enzyme in vivo (13). 
The domain organization of the CaN A subunit has been 
elucidated through the work of several groups. Limited 
proteolysis of calcineurin showed distinct CaN B-binding, CaM-
binding, and autoinhibitory domains, along with a 44 kDa N-
terminal catalytic core (14-17). The putative CaM-binding 
region was identified by sequence homology to other CaM-binding 
peptides (18), while the autoinhibitory domain was identified to 
be 40-50 residues C-terminal from the CaM-binding sequence by 
peptide inhibition (19) and mutagenesis (20) studies. It is 
thought that the autoinhibitory region of CaN A acts to inhibit 
the phosphatase activity of the catalytic core. Binding of 
calmodulin presumably relieves this inhibition by displacing the 
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inhibitory region from the catalytic domain. However, the 
autoinhibitory domain of calcineurin is apparently not a 
"pseudosubstrate" for the active site of CaN A, since the 
peptide corresponding to the sequence of the autoinhibitory 
region is noncompetitive with respect to substrate (19). 
Most calmodulin binding domains are predicted to form basic 
amphiphilic a-helices (21). The putative calmodulin binding 
domain of calcineurin is also predicted to form such a helix and 
contains five arginine residues (18). Many studies on the 
interaction between calmodulin and the enzymes which it 
activates have focused on the role of hydrophobic residues in 
the calmodulin binding site of the enzyme (21,22). However, not 
much is known about the importantance of electrostatic 
interactions in calmodulin-target binding. What is known is 
that all seven basic residues in peptide corresponding to the 
CaM-binding sequence of smooth muscle myosin light chain kinase 
(smMLCK) make salt bridges with residues in calmodulin (23). 
Previously, using peptidylarginine deiminase, we had 
generated a form of bovine brain calcineurin in which three 
positively charged arginine residues had been converted to the 
neutral amino acid citrulline (24). These citrulline were 
localized to the 14 kDa C-terminal region of the CaN A subunit, 
on which the CaM binding site is located. Modification of these 
arginines resulted in reduction of calcineurin phosphatase 
activity in our assay apparently due to a marked decrease in 
calmodulin binding affinity to calcineurin. Our results 
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suggested that not all of the arginines converted were necessary 
for the effects seen when these modifications were introduced. 
Therefore we wanted to localize further the modification(s) 
relevant to these observed effects. In this paper, we describe 
the deimination of a truncated form of CaN A in which C-terminal 
sequences of the autoinhibitory region, but not the putative 
calmodulin-binding domain, have been deleted- We find evidence 
suggesting that the relevant citrulline modification lies not in 
the previously described putative calmodulin-binding domain, but 
in the deleted C-terminal region of the CaN A subunit. 
Experimental Procedures 
Materials All buffers, as well as EGTA and phenyl-
Sepharose, were purchased from Sigma. All other chemicals were 
from Fisher. PVDF membrane and HRP-conjugated goat anti-rabbit 
IgG were from BioRad. Serum-free insect cell media, Sf21 cells, 
and 3,3'-Diaminobenzidine tetrachloride (DAB) were from Life 
Technologies, Inc (Gaithersburg, MD). Recombinant baculoviruses 
containing the cDNA's for rat brain CaNsoo/ CaN457 truncation 
mutant, and CaN B have been described (20,25) and were kindly 
provided by Dr. Thomas Soderling (Vollum Institute, Oregon 
Health Sciences University). Rabbit anti-calcineurin antibody 
was a generous gift from Frank Rusnak (Mayo Clinic, MN). 
Antibody recognizing modified citrulline residues in proteins 
has been described previously (26). [y-^^PJ-ATP was from ION 
Pharmaceuticals (Costa Mesa, CA). 
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Enzymes and proteins Calmodulin was purified from 
bovine brain using the method of Sharma and Wang (27) modified 
to include phenyl-Sepharose after DE-52 chromatography, 
according to Gopolakushna and Anderson (28). CaM-Sepharose was 
prepared by the method of Sharma et al. (29). Peptidylarginine 
deiminase was purified from frozen rabbit skeletal muscle, 
according to Takahara et al. (30). Clostripain was purchased 
from Sigma. Protein concentration was determined by the 
method of Bradford (31). 
Expression and purification of recombinant calcineurins 
The expression of baculoviruses containing CaN A and CaN B 
cDNA's in Sf9 cells in media containing serum has been described 
(20,25). Expression and purification of these calcineurins were 
carried out similarly, with the following modifications. Sf21 
cells in serum-free suspension culture were infected with third-
passage CaN A and CaN B viruses at a multiplicity of infection 
of 5 and 7, respectively. The cells were then cultured at an 
initial density of 3 x 10^ cells/ml in 40.ml serum-free insect 
cell media. Cells were harvested between 90-100 hours 
postinfection by centrifugation at 1000 x g for 10 minutes and 
resuspended in 20 ml buffer A (25 mM Tris, pH 7.8, 3 niM MgS04, 2 
mM EGTA, 2 mM EDTA, 20 mM 2-mercaptoethanol, 0.5 mM 
phenylmethylsulfonyl fluoride (PMSF), 5 mg/L leupeptin, 5 mg/L 
aprotinin, and 200 mg/L benzamidine). The resuspended cells 
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were either stored at -70°C or processed iiranediately for 
purification. 
To lyse the cells for calcineurin purification, the cells 
were sonicated 5 x 15 seconds at 45 second intervals using a 
Branson sonifer 450. The homogenate was centrifuged at 20,000 x 
g for 30 minutes at 4°C and the supernatant made 45% in ammonium 
sulfate. Proteins were stirred for 10 minutes after addition of 
ammonium sulfate, then left on ice for 50 minutes. Precipitated 
proteins were collected by centrifugation at 11,000 x g for 30 
minutes. The pellet was resuspended in 4 ml EGTA buffer (25 mM 
Tris, pH 7.8, 3 mM MgS04, 0.5 mM DTT, 0.1 mM EGTA) plus 0.5 mM 
PMSF, 5 mg/L leupeptin, 5 mg/L aprotinin, and 200 mg/L 
benzamidine and combined with 30 ml CaM-Sepharose in the same 
buffer. Calcium chloride was added to a final concentration of 
2 mM, and the slurry was stirred intermittently for 30 minutes. 
The CaM-Sepharose was then washed with the following buffers on 
a glass scintered funnel: CaCl2 buffer (25 mM Tris, pH 7.8, 3 mM 
MgS04, 0.5 mM DTT, 0.2 mM CaCla) containing 2 mM CaCl2, 5 x 50 
ml; CaCl2 buffer alone, 5 x 50 ml; and CaCl2 buffer containing 
0.3 M NaCl, 5 X 50 ml. All above CaCl2 buffers were 
supplemented with 0.5 mM PMSF and 200 mg/L benzamidine. 
Calcineurin was eluted from the washed CaM-Sepharose with EGTA 
buffer containing 0.5 mM EGTA, 0.3 M NaCl, 0.5 mM PMSF, and 200 
mg/L benzamidine. The protein peak was concentrated with an 
Amicon PM-10 membrane, dialyzed overnight against EGTA buffer 
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containing 20% glycerol, aliquotted, and stored at -70°C until 
use. 
Calcineurin assays Preparation of 32p_iabeied RCMM-
lysozyme was carried out as described (32,33). Typical 
calcineurin assays were done in 25 mM MOPS, pH 7.0, 1 mM MnCl2, 
and the indicated concentrations of calmodulin (0.75-10 pg/ral), 
with 18 pH ^2p_RCMM-lysozyme as substrate and 3 ;jg/ml 
calcineurin, in a reaction volume of 60 ^ 1. The reaction was 
terminated by addition of 100 ^1 ice-cold 20% TCA. Protein 
substrate was allowed to precipitate on ice for 60 minutes, then 
the reaction was centrifuged at 15000 x g for 5 minutes. 
Released 32.phosphate in the supernatant was counted in 10 ml 
scintillant. 
Deimination of expressed calcineurins Deimination of 
expressed calcineurins was performed essentially as described 
(24). Briefly, reactions were carried out for 60 minutes in 50 
mM Hepes, pH 7.2, 5 iiiM CaCl2, 5 mM DTT, 0.7-1.1 mg/ml 
calcineurin, and 40 ;jg/ml deiminase. The full length CaNsoo was 
assayed in 10 ^g/ml CaM in a typical calcineurin assay, while 
truncated CaN457 was assayed in 0.75, 1.5, 3.0, and 10 ;;g/ml 
CaM. 
Sodium-dodecvl sulfate-polvacrvlamide gel electrophoresis, 
electroblottinq, and Western analysis for citrulline 
Calcineurin samples were separated by SDS-PAGE (34) on a 12.5% 
poly aery lamide gel and elect roblotted onto PVDF using 10 mM 
CAPS, pH 11.0, in 10% methanol, or onto nitrocellulose using 25 
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mM Tris, pH 8.3, and 192 mM glycine in 20 methanol (constant 300 
mA for 1 h). The PVDF membrane was stained with 0.025% (w/v) 
Coomassie brilliant blue R250 in 50% methanol (v/v) for amino 
acid analysis of protein bands, while nitrocellulose membranes 
were processed for Western analysis using an anti-modified 
citrulline antibody as described (24,26). Detection of 
immunoreactive bands was performed using the DAB/H2O2 
colorimetric method as described (24). 
Amino Acid Analysis Protein bands (CaNsoo and CaN457 ) 
separated by SDS-PAGE and electroblotted onto PVDF were excised 
from the membrane and subjected to amino acid analysis. The 
analysis was performed on an Applied Biosystems 42 OA amino acid 
analyzer by the Iowa State University Protein Facility. 
Quantitation of citrulline was determined from the citrulline 
plus ornithine peaks in the HPLC trace, because degradation of 
citrulline into ornithine occurs during the acid hydrolysis 
(35). 
Results 
Expression of CaNspn and CaN457 truncation mutants The 
sequence of the CaN A subunit, along with a truncation mutant 
engineered so that a stop codon was introduced at amino acid 
457, is outlined in Figure 1. The truncation mutant contains 
the full putative calmodulin domain, as described by Kincaid and 
Martin (18). However, the autoinhibitory region, as determined 
Figure 1. Rat brain calcineurin A subunit amino acid 
sequence deduced from cDNA. Residues singly 
underlined denote the putative calmodulin binding 
domain as defined by Kincaid and Martin (18). 
Residues doubly underlined denote the 
autoinhibitory domain as described by Hashimoto et 
al. (19). (*) marks the truncation point for CaN 
A457, while (**) is the natural stop codon for CaN 
Asoo- ^ are the arginines that have been mutated 
to alanine in the double mutant described by 
Perrino et al. (20). 
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MKEGRLEESV ALRIITEGAS ILRQEKNLLD IDAPVTVCGD IHGQFFDLMK 
LFEVGGSPAN TRYLFLGDYV DRGYFSIECV LYLWALKILY PKTLFLLRGN 
HECRHLTEYF TFKQECKIKY SERVYDACMD AFDCLPLAAL MNQQFLCVHG 
GLSPEINTLD DIRKLDRFKE PPAYGPMCDI LWSDPLEDFG NEKTQEHFTH 
NTVRGCSYFY SYPAVCDFLQ HNNLLSILRA HEAQDAGYRM YRKSQTTGFP 
SLITIFSAPN YLDVYNNKAA VLKYENNVMN IRQFNCSPHP YWLPNFMDVF 
TWSLPFVGEK VTEMLVNVLN ICSDDELGSE EDGFDGATAA ARKEVIRNKI 
RAIGKMARVF SVLREESESV LTLKGLTPTG MLPSGVLSGG KQTLQSAIKG 
FSPQHK*ITSF EEAKGLDRIN ERMPPRRDAM PSDANLNSIN KALASETNGT 
DSNGSNSSNI Q** 
75 
by peptide inhibition studies (19) and mutagenesis (20), has 
been deleted. The only arginines which still exist in the 
truncation mutant are those of the catalytic core and the five 
arginines in the putative calmodulin-binding domain. 
Since the CaN B subunit has been shown to be important for 
full activation of the phosphatase activity of the CaN A 
subunit, co-expression of CaN A and CaN B viruses was carried 
out using the baculovirus expression system. At first, we 
attempted to monitor calcineurin expression using an a-CaN 
polyclonal antibody. However, although the antibody recognizes 
purified bovine brain calcineurin, the antibody did not react to 
the expressed rat calcineurin (data not shown), we were able to 
show expression of calcineurin by SDS-PAGE of the homogenates of 
Sf21 cells infected with CaN A and CaN B viruses (Fig. 2). 
After CaM-Sepharose affinity chromatography, calcineurin was 
purified to 90-95% homogeneity, as judged by SDS-PAGE (Fig. 2). 
The expressed CaN B doublet in Figure 2 is a result of the 
myristylated (faster migrating) and non-myrisylated (slower 
migrating) forms of the CaN B subunit, as shown previously (20). 
Calmodulin dependence of expressed calcineurins The 
truncated form of calcineurin, CaN457, had previously been found 
to exhibit greater phosphatase activity than wild type 
calcineurin in the presence and absence of calmodulin (20), 
consistent with the deletion of the autoinhibitory region. 
However, CaN457 still is activated by increasing concentrations 
of calmodulin (Fig. 3), presumably because the enzyme still 
Figure 2. (A) Coomassie-stained 12.5% SDS-PAGE of Sf21 cell 
homogenates expressing the CaN Asoo/CaN B or CaN 
A457/CaN B recombinant baculoviruses. Sf21 insect 
cells were made to express CaN a500 or CaNA457 , 
along with CaN B, harvested 90-100 p.i., and 
resuspended in buffer A, as described in the 
Experimental Procedures. Cells were sonicated and 
40 ^ 1 of each homogenate was loaded onto each 
lane. Lane 1, CaN Asoo/CaN B homogenate; Lane 2, 
CaN A457/CaN B homogenate. The CaN B doublet could 
not be accurately visuallized in CaN-expressing 
homogenates due to co-migrating bands in non-
expressing control homogenates (not shown). (B) 
Coomassie-stained 10% SDS-PAGE of calcineurins 
purified from baculovirus expression system. 
CaNsoc (lane 2) and CaN457 (lane 3) were purified 
using CaM-Sepharose affinity chromatography as 
described in the Experimental Procedures. Lane 1: 
molecular weight markers, 97, 66, 45, 31, 22, 14 
kDa. 10 ;jg total protein was loaded onto each 
lane. 
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(figure 2 continued) 
Figure 3. Calmodulin activation curves of CaNsoo and CaN4S7. 
CaNsoo (•) and CaN457 (•) were assayed as described 
in the Experimental Procedures, with increasing 
calmodulin concentrations in the assays. 
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contains the calmodulin binding site and sequences just N-
terminal to the identified autoinhibitory region have recently 
been shovm to have autoinhibitory properties (20). As expected, 
the phosphatase activity of CaN457 is greater than that of full-
length CaNsoo in the presence and absence of calmodulin. CaN457 
can also be activated to the same level as CaNsoo t>y slightly 
lower calmodulin concentrations, since Kact of CaN457 by 
calmodulin is 1.1 ± 0.1 ^g/ml CaM, while Kact of CaNsoo by 
calmodulin is 2.7 ± 0.8 jjq/wl CaM. Therefore, lower calmodulin 
concentrations were used in calcineurin assays for CaN457 to 
attempt to detect decreased activity due to incubation of CaN457 
with the deiminase, as described in the Experimental Procedures 
and also in the next section. 
Deimination of expressed calcineurins When bovine brain 
calcineurin is incubated with peptidylarginine deiminase, its 
Mn^+ZcaM-stimulated phosphatase activity is reduced to 20-40% of 
the original activity within one hour (24). This was also 
observed with the full-length rat calcineurin expressed in S21 
cells (Fig. 4A). Including calmodulin in the deimination 
reaction protects full-length calcineurin from this loss of 
activity (Fig. 5), as seen with bovine brain calcineurin (24), 
and even results in a slight activation of the enzyme. However, 
when the truncated CaN457 is incubated with the deiminase in the 
absence of calmodulin, no reduction in activity is observed 
after 90 minutes (Fig. 4B). 
Figure 4. Time courses of incubation of CaNsoo and CaN457 
with deiminase. CaNsoo or CaN457, at 0.9 mg/ml, 
was incubated with the deiminase as described in 
the Experimental Procedures. (A) Time course of 
CaNsoo control (•) and CaNsoo incubated with 
deiminase (•). (B) Time course of CaN4S7 control 
(•) and CaN457 incubated with deiminase (O). In 
this particular experiment, CaN457 was assayed in 3 
;jg/ml CaM. Other attempts at detecting a 
reduction in CaN457 activity using differing 
amounts of calmodulin in the assay (0.75, 1.5, and 
10 /jg/ml CaM) gave similar results. 
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(figure 4 continued) 
Figure 5. Calmodulin protection of the reduction in 
phosphatase activity of CaNsoo during incubation 
with deiminase. The deimination reaction was 
performed as in Figure 4, except that calmodulin 
(42 3.7-fold molar excess over CaNsoo) was 
included in the reaction as indicated, then 
assayed. 
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When both of these calcineurins were assayed before and 
after deimination, different concentrations of calmodulin were 
used in the assay to keep both reactions within the linear 
range. A concentration of 10 jjg/ml calmodulin was used for 
assaying the full-length CaNsoo, while 0.75, 1.5, 3.0, and 10.0 
;jg/ml calmodulin was used for the CaN457 assay. Note that the 
CaNsoo assay contained almost saturating calmodulin, while most 
CaN457 assays were performed in subsaturating calmodulin (Fig. 
3). The loss of activity of deiminated bovine brain calcineurin 
was previously observed under saturating calmodulin conditions, 
and a very high concentration of calmodulin was required to 
activate deiminated bovine brain calcineruin (24). Since loss 
of activity upon deimination of bovine brain calcineurin was 
observed under saturating calmodulin conditions, if loss of 
activity upon deimination of CaN457 was to be detected, it 
certainly would be observed under subsaturating calmodulin 
conditions. 
Localization of relevant modified arqinines in calcineurin 
Deimination of full-length rat brain calcineurin, like bovine 
brain calcineurin, results in deimination of arginine residues 
only in the CaN A subunit (Fig. 6, lane 1). Unlike bovine brain 
calcineurin, proteolysis of the rat brain CaNsoo subunit by 
clostripain, which results in the loss of the 14 kDa C-terminal 
region of CaNsoo f does not cleave all citrulline residues from 
the 44 kDa catalytic core (Fig. 6, lane 2). Although the 
Figure 6. Western analysis of deiminated CaNsoo and CaN457 
using an anti-citrulline antibody. 5 pg 
deiminated CaNsoo {lanes 1 and 2) or 5 ^ g 
deiminated CaN457 were loaded onto a 12.5% SDS-PAGE 
gel. Lanes 2 and 4 are CaNsoo and CaN457 , 
respectively, treated with 2 U clostripain as 
described (24). After electrophoresis, the 
separated subunits and proteolytic fragments were 
electroblotted onto nitrocellulose and analyzed 
for the presence of citrulline using an anti-
citrulline antibody (see Experimental Procedures). 
No citrulline was observed in the CaN B subunit of 
either expressed CaN, while citrulline was present 
in the 51 kDa CaN A500 subunit (lane 1) and in the 
57 kDa CaN A457 subunit (lane 3). The lower bands 
in the doublets in lanes 2 and 4 (both digested 
CaN's) correspond to the previously observed 44 
kDa catalytic core (24). The slower migrating 
bands in the doublets presumably originate from 
each respective CaN A subunit and most probably 
represents a digested CaN A intermediate in the 
proteolysis reaction. 
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catalytic core appears to still contain citrulline, proteolysis 
of the C-terminal domain from the catalytic core relieves the 
inactivation caused by deimination to the level of control 
digested rat brain calcineurin (Fig. 7), an observation seen 
with bovine brain calcineurin (24). Therefore, another 
modification of an arginine(s) irrelevant to the reduction in 
activity upon deimination seems to be taking place in the 
catalytic core of the expressed rat brain calcineurin. 
Amino acid analysis of full-length rat brain calcineurin 
shows an average of 3.85 citrulline residues in the CaNsoo 
subunit, compared to an average of 2.95 citrulline in bovine 
brain. The three citrulline in the bovine brain calcineurin 
were localized to the 14 kDa C-terminal region of CaN A, with 
none in the catalytic core, so the extra citrulline found in the 
rat brain calcineurin may be due to modification of an arginine 
in the N-terminal catalytic core which is not modified in bovine 
brain. This is possible since sequence variations exist between 
the catalytic cores of bovine and rat brain calcineurins, 
especially in the extreme N-terminal region, which may be 
accessible to the deiminase (25,36, Fig. 8). 
Western analysis of the truncated CaN457 also reveals that 
only the CaN A457 subunit of the truncated enzyme is deiminated 
(Fig. 6, lane 3). Upon proteolysis with clostripain, the 44 kDa 
fragment also contains citrulline, suggesting that the same 
modification(s) occuring in the N-terminal core of full-length 
Figure 7. Reactivation of CaNsoo upon limited proteolysis 
with clostripain. Digestion of control and 
deiminated full-length CaNsoo was performed as 
previously described (24), then assayed. The 
closed bars show the activity of undigested 
control and deiminated CaNsoo in the presence of 10 
pq/ml calmodulin. The open bars show the activity 
of digested control and deiminated CaNsoo in the 
presence of 10 /ig/ml calmodulin. 
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Figure 8. N-terminal sequence comparison of bovine and rat 
brain calcineurins. N-terminal sequences of 
bovine and rat brain calcineurin differ so that 
recognition of arginines by the deiminase may also 
differ. Peptidylarginine deiminase appears to 
prefer certain arginines over others, depending on 
the sequence surrounding the arginines; however, 
no strict sequence specificity can be defined 
(35). N-terminal sequences are from references 25 
and 36. 
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calcineurin is also taking place in the truncated form of 
calcineurin (Fig. 6, lane 4). The 44 kDa band from CaN457 is 
not as intense as the 44 kDa band from CaNsoo/ which suggests 
that the truncated calcineurin may be more susceptible to 
protease treatment. Amino acid analysis of CaN457 shows an 
average of 3.35 citrulline/mol CaN457, 0.5 lower than full-
length CaNsoo- This suggests that possibly one arginine in the 
region deleted in CaN457 is being modified in the full-length 
form of calcineurin, since the amount of citrulline is decreased 
in CaN457 . Because no loss of activity is observed when CaN457 
is incubated with the deiminase, an arginine that is deleted in 
the truncated form may be responsible for the loss of activity 
and reduced calmodulin binding of full-length calcineurin upon 
deimination. 
Discussion 
We have studied the effects of deimination on two 
recombinant calcineurins, one with a full-length CaN A subunit 
and the other with a truncated CaN A subunit in which certain 
autoinhibitory sequences have been deleted. Deimination of the 
full length calcineurin results in the reduction of its 
phosphatase activity to 20-40% of its original activity, as 
observed in the deimination of purified bovine brain 
calcinerurin (24). Cleaving the C-terminal domain from the 
deiminated CaNsoo using clostripain reactivates the phosphatase 
activity to the level of digested control CaNsoo- This suggests 
that modification of an arginine(s) in this C-terminal domain is 
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responsible for the loss of activity upon deimination. The 
observed loss of activity has been previously shown to be due to 
reduced calmodulin activation of and binding to calcineurin, 
using purified bovine brain calcineurin (24). 
Unlike the full-length rat brain CaNsoo/ the deiminated 
truncated CaN457 does not display reduced activity, even in the 
presence of several different subsaturating calmodulin 
concentrations. There could be several explanations for this 
observation. Perhaps the most interesting explanation is that 
the relevent arginine modification is taking place on CaNsoo in 
the so-called autoinhibitory domain instead of the putative 
calmodulin-binding domain. This modification in the 
autoinhibitory domain could be affecting CaM-binding, thus the 
reduction in CaM-stimulated activity upon deimination of full-
length CaNsoo- This would suggest that sequences in both the 
previously characterized calmodulin binding site and 
autoinhibitory region of calcineurin are important for complete 
CaM-binding and activation of calcineurin, when both regions are 
present. When both regions are not present, as in truncated 
CaN457, calmodulin can bind and presumably activate 
calcineurin's phosphatase activity to a greater degree for two 
possible reasons: (1) the additional constraint of calmodulin 
having to bind to additional C-terminal sequences would be gone 
and (2) a portion of the autoinhibitory domain is not binding to 
the catalytic core. Indeed, assaying deiminated CaN457 in the 
presence of several calmodulin concentrations suggests that CaM-
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activation of CaN457 is not affected by deimination of residues 
outside of the deleted autoinhibitory region. On the other 
hand, calmodulin binding, and, in turn, calmodulin activation of 
purified bovine brain calcineurin is affected by deimination. 
There is precedence for calmodulin binding to two distinct sites 
in an enzyme; in phosphorylase kinase catalytic subunit, the C-
terminal region, on which the autoinhibitory domain is located, 
contains two distinct calmodulin binding sites which bind 
calmodulin simultaneously (37). 
Additional evidence that the arginine modification relevant 
to the loss of activity and presumed reduction in CaM binding is 
in the autoinhibitory region of CaN A is the amino acid analysis 
of both deiminated forms of calcineurin described in this paper. 
The full-length CaNsoo contains 3.85 citrulline residues, while 
the citrulline is decreased to 3.35 in the truncated form. If 
the assumption is made that the same modifications are taking 
place in the catalytic core and/or previously identified CaM 
binding regions of both full-length and truncated calcineurin, 
then the reduced amount of citrulline in truncated CaN457 could 
be due to the deletion of the autoinhibitory region. Since, in 
the 14 kDa C-terminus of rat brain CaN A, no other arginine 
residues outside of the putative calmodulin binding or 
autoinhibitory domains exist, the decreased amount of citrulline 
in the truncated CaN457 might mean that the additional arginine 
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being modified in the full-length rat brain calcineurin is in 
the autoinhibitory region of CaNsoo* 
A second explanation for no observed loss of activity 
upon deimination of CaN457 is that modification of a relevant 
arginine is still occuring in the putative CaM-binding domain of 
truncated CaN457 upon deimination, but loss of activity is not 
seen because additional secondary structure or sequences 
necessary for calmodulin activation or the observed loss of 
activity are not present. Another interpretation of the results 
could be that modification of an arginine to citrulline in the 
autoinhibitory domain causes an alternate or distorted secondary 
structure of the C-terminus of CaN A, resulting in decreased 
calmodulin binding and/or activation. In CaN457, this would not 
be possible since the autoinhibitory domain is deleted. 
Finally, modification of an arginine in the autoinhibitory 
domain to citrulline could cause an increase in the affinity for 
its binding to the catalytic core. Again, this would not be 
possible in CaN457, for this region is deleted. 
A double arginine mutant in the autoinhibitory region of 
CaN A has already been described (20, see also Fig. 1). in this 
mutant, the Ca2"^/CaM-stimulated activity is activated 2-fold, as 
compared to the Ca^+ZcaM-dependent activity of the wild type, 
while the phosphatase activity of the mutant in the presence of 
Ca2+ only (no CaM) is 3-fold that of Ca^^-stimulated wild type. 
The Ca2+ only activation of the mutant can be explained; the 
activation is probably due to decreased binding of the 
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autoinhibitory domain to the catalytic core upon mutation of 
these arginines (20). However, interpretation of the data is 
difficult as it pertains to CaM binding and activation of 
calcineurin, since those calcineurin assays were performed in 
saturating calmodulin. How well calmodulin binds to or activates 
the mutant is not clear. Therefore, single site-directed 
arginine mutations should provide more information to determine 
which arginine(s) are important for CaM-dependent loss of 
activity and binding to calcineurin upon its deimination. This 
information would tell us if these arginine(s) are located in 
the putative calmodulin binding domain, autoinhibitory domain, 
or both. 
Contributions of authors: Tatsuo Senshu provided the anti-
modified citrulline antibody for the Western blots. All other 
experiments were conducted and the manuscript was written by 
Jennifer Imparl-Radosevich, under the direction of Donald 
Graves. 
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Abstract 
We have separated and identified two components derived 
from cinnamon, the "yellow" and "void" fractions, both of which 
inhibit PTP-1 activity and increase insulin receptor kinase 
catalytic autophosphorylation. The kinetic analysis of PTP-1 
inhibition by the void fraction shows that it exhibits a time-
dependent, irreversible inactivation of PTP-1 and is 
noncompetitive with respect to substrate, while the yellow peak 
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exhibits no such time-dependent inactivation of PTP-1. These 
fractions give high biological response, as measured by glucose 
oxidation in the rat epididymal fat cell assay. Wortmannin, a 
potent PI 3'-kinase inhibitor, decreases the biological 
responses to insulin and the mixture of these fractions (denoted 
109301F) similarly, indicating that the cinnamon fraction is 
affecting an element(s) upstream of PI 3'-kinase. All these 
data may suggest that, in vivo, these fractions derived from 
cinnamon may be acting to stimulate insulin receptor kinase 
activity while it inhibiting PTPases which attenuate the 
receptor kinase signal. We also have partially characterized 
the yellow fraction, and mass spectrometry of this fraction 
shows that it contains a compound with a molecular weight of 
346. 
Introduction 
Severe obesity or non-insulin dependent diabetes mellitus 
(NIDDM) is characterized by the diminished ability of insulin-
dependent tissues to respond to insulin (1). This insulin-
resistance could be the result of a number of defects in the 
insulin signalling pathway (2-6). However, much focus has been 
put on evidence that insulin receptor kinase autophosphorylation 
and subsequent phosphorylation of its principal substrate, IRS-
1, are markedly decreased in insulin-responsive tissues of 
subjects with severe obesity or NIDDM (1-9). Dephosphorylation 
of the receptor J3-subunit is associated with the deactivation of 
its kinase activity and therefore is associated with insulin 
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signal down-regulation (10). Recently, Nadiv et al. (11) have 
shown that the decreased degree of phosphorylation of the 
insulin receptor in the insulin-resistant condition may be due 
to the action of protein tyrosine phosphatases. The authors 
observed elevated cytosolic PTPase activity directed against the 
p-subunit of the insulin receptor in aged, insulin-resistant 
rats. Begum et al. (12) also reported increased PTPase activity 
toward intact insulin receptors in diabetic rat adipocytes, 
although they found the elevated PTPase activity in the 
particulate fraction. Regardless of the subcellular 
localization of the PTPases involved, enhancement of PTPase 
activity toward the insulin receptor kinase in insulin-dependent 
tissues apparently results in impaired insulin receptor 
signalling in those tissues. 
One of the prime candidate PTPases likely responsible for 
dephosphorylation of the insulin receptor in vivo is PTP-lB. 
PTP-lB preferentially dephosphorylates a phosphopeptide 
encompassing the autophosphorylation domain of the insulin 
receptor B-subunit on Tyr-1150 or Tyr-1151 (13), sites critical 
for deactivation of the receptor kinase (10). When PTP-lB and 
insulin receptors were co-expressed to high levels, insulin 
receptor autophosphoirylation was inhibited (14). Even PTP-lB 
mRNA levels are responsive to insulin. Treatment of rat 
hematoma cells with 100 nM insulin increases the abundance of 
the two mRNA's encoding PTP-lB by 1.6- and 3.1-fold, with no 
significant effect on the abundance of mRNA encoding the 
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receptor-type phosphatases LAR or LRP (15). Therefore, PTP-IB 
may provide feedback regulation of insulin signalling. 
The development of oral anti-diabetic agents which enhance 
insulin sensitivity in insulin-dependent tissues has received 
much attention (16-18). One anti-diabetic agent, pioglitazone, 
has been shovm to increase insulin sensitivity through its 
ability to reactivate insulin receptor kinase 
autophosphorylation (19,20). Pioglitazone does not act directly 
on the receptor, since incubation of insulin receptors and 
pioglitazone in vitro does not result in increased receptor 
kinase autophosphorylation (19). There is now strong evidence 
that this indirect effect of pioglitazone on receptor 
autophosphorylation is due, at least in part, to normalization 
of elevated PTPase activities in insulin-unresponsive cells 
(21). Preliminary evidence suggests that the cytosolic PTPase 
responsible for the normalization of elevated PTPase is PTP-IB 
(21). Therefore, some anti-diabetic agents may act to decrease 
elevated PTPase activities in insulin-dependent tissues, 
restoring insulin sensitivity to those tissues by allowing 
autophosphorylation of the insulin receptor and resultant 
insulin signal transduction. 
Chromium has been shown to be required for maintaining 
normal glucose tolerance (22-24). Therefore, a slight chromium 
deficiency in humans could mean an increased risk of developing 
diabetes (25). However, there is mounting evidence that the 
chromium responsible for glucose tolerance maintainance is not 
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that of a simple inorganic chromium, such as chromium chloride, 
but that the chromium must be complexed with certain ligands to 
exert its biological activity (25-27). Two known biological 
chromium complexes have received much attention. The first, 
termed glucose tolerance factor (GTF), was originally extracted 
from Brewer's yeast and was found to contain chromium, nicotinic 
acid, glycine, glutamic acid, and cysteine (28). The second is 
known as low-molecular weight chromium binding ligand (LMWCr) 
(29). Having a molecular weight of -1500, LMWCr contains 
chromium, aspartic acid, glutamic acid, and cysteine, but no 
nicotinic acid. LMWCr has been shown to exhibit biological 
activity, as detected by glucose oxidation in isolated fat 
cells, similarly to that of GTF (29). 
Some extracts of certain spices also exhibit insulin 
potentiating activity in the rat epididymal fat cell assay (30-
31). One of the spices which best potentiates insulin's effects 
in these cells is cinnamon (30). It is not known how cinnamon 
exerts its effect. It apparently is not due to the action of 
biological chromium in the spice, since chromium concentration 
in spices is not correlated with their insulin potentiating 
activity (30). A number of phenols, aldehydes, and acids have 
been identified in extracts of cinnamon, including eugenol, 
cinnamaldehyde, and cinnamic acid (32). It remains to be seen 
if any of these identified compounds are responsible for 
cinnamon's biological activity, or if a previously unidentified 
compound(s) is responsible. 
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The purpose of this work was to characterize a possible 
mechanisin(s) by which cinnamon potentiates insulin's activity. 
A fraction from cinnamon, denoted 109301F, exhibits high 
biological activity in the rat epididymal fat cell assay. We 
tested the hypothesis that this fraction may potentiate 
insulin's effects by inhibiting a PTPase which dephosphorylates 
the insulin receptor kinase. We find that the fraction does 
indeed inhibit PTP-1, a rat homolog of PTP-IB, and that the 
inhibition is not likely due to the action of contaminating 
chromium. Surprisingly, the cinnamon fraction 109301F also 
activates insulin receptor catalytic domain autophosphorylation. 
This may indicate that 109301F is acting to stimulate insulin 
receptor kinase while it inhibits a PTPase which may otherwise 
attenuate the stimulated kinase activity. We further describe 
the separation of 109301F into two components which exhibit 
receptor kinase activation and PTP-1 inhibitory properties, as 
well as biological activity in the rat fat cell assay. One of 
the two components appears to have molecular weight of 346, as 
determined by mass spectrometry. 
Experimental Procedures 
Materials All buffers, along with polyGluTyr (4:1), 
alkaline phosphatase, wortmannin, and pNPP, were purchased from 
Sigma. All other chemicals were from Fisher. Serum-free insect 
cell media was from Life Technologies, Inc. (Gaithersburg, MD). 
[Y-22pj_ATP was from ICN Pharmaceuticals (Costa Mesa, CA). 
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Enzymes Rat brain PTP-1 truncated at amino amino acid 
323 to eliminate a hydrophobic region near the C-terminus was 
expressed as a GST-fusion and purified to homogeneity as 
described (33). The intracellular domain of the insulin 
receptor was expressed in the baculovirus expression system and 
purified as described (34), except that Sf21 cells instead of 
Sf9 cells were used for kinase expression and cells were 
harvested 96 h post infection. The expressed kinase domain 
contains the entire intracellular domain of the J3-subunit of the 
human insulin receptor, but no sequences in the insulin-binding 
extracellular region. Therefore, kinase activity was insulin-
independent and kinase activity was measured in the absence of 
insulin. Calcineurin was purified from Sf21 cells expressing 
the CaN A and CaN B subunits from rat brain essentially as 
described (35). 
PTP-1 assays was prepared as 
described (36). For most assays, 20 pi enzyme diluted in assay 
buffer (50 mM Tris, pH 7.0, 0.05 mM EDTA, 1 mg/ml BSA, and 0.3% 
2-mercaptoethanol) was added to 20 ^ 1 cinnamon compound or ddH20 
and 20 pi 300 nM 32_p_RCMM_iysozyme, also diluted in assay 
buffer. Reaction was allowed to proceed so that less than 30% 
of the 32p v/as released from the 32p_RCMM-lyso2yme (5-20 
minutes, depending on enzyme dilution), then terminated by 
addition of 100 pi ice-cold 20% TCA. After 10 minutes on ice, 
the reaction was centrifuged at 15000 x g for 2 minutes, and the 
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supernatant counted in 10 ml scintillant. 32p_RCMM-lysozyme as 
substrate for PTP-1 in all experiments, except where indicated, 
in which case pNPP was utilized. 
PTP-1 activity toward pNPP was determined in the above 
assay buffer with 10 mM pNPP in a final reaction volume of 30 
^1. Reaction was terminated by the addition of 0.5 ml 0.2 N 
NaOH, and the resulting pNP was measured at 410 nm in a Beckman 
spectrophotometer. 
Insulin receptor kinase domain assays For 
autophosphorylation assays, 7.1 jjg kinase domain (0.24 mg/ml 
final concentration of kinase) was added to 1 mM [y-^^PJ-ATP in 
50 mM Hepes, pH 7.4, 20 mM MgCl2, and 4 mM MnCl2, in the 
presence or absence of cinnamon compound. The reaction was 
terminated by spotting 15 pi of reaction mixture on Whatman P-81 
paper. The papers were washed 2 x 15 minutes in 0.5% H3PO4 and 1 
X 5 minutes in ethanol. The dried papers were counted in 10 ml 
scintillant. For determining kinase activity toward exogenous 
substrate, the concentration of insulin receptor kinase domain 
was reduced to 20 jug/ml, and 1 mg/ml polyGluTyr (4:1) was 
included in the assay. Reaction was terminated by spotting 15 
^1 of the reaction on Whatman 3MM paper. The papers were washed 
3 X 30 minutes in 10% TCA/1% pyrophosphate and 1 x 10 minutes in 
ethanol. The dried papers were again counted in 10 ml 
scintillant. 
Ill 
Purification of compounds from cinnamon. 1 g cinnamon 
was extracted with 20 ml O.lN NH4OH, as described (31). The pH 
was adjusted to 2.0, and the precipitate discarded. The pH of 
the supernatant was readjusted with NH4OH to pH 10.0 and run on 
a Sephadex G-lOO column in the same buffer. The void volumn was 
discarded and the biologically active peak from the column run 
on a Sephadex G-50 column. The void volumn from the Sephadex G-
50 column was again discarded, while the biologically active 
peak was retained (this fraction was denoted 109301F). The 
above procedures were performed twice, once with O.lN NH4OH 
only, and once with O.lN NH4OH plus 20 mM sulfite, pH 10.0, 
which seemed to stabilize the biological activity through the 
columns. The initial studies of the effect of cinnamon 
compound(s) were performed with 109301F, obtained from the first 
chromotography run with no sulfite (O.lN NH4OH only). The 
fraction obtained from the second Sephadex G-50 column, run in 
0.1 N NH4OH plus sulfite, and denoted 109301F-B, was further 
purified through a Sephadex G-25 column run in ddH20 to obtain 
the "yellow" and "void" fractions. 
Rat epididvmal fat cell assay Adipocyte isolation from 
rat epididymal fat pads was carried out as described (31). 
Glucose oxidation measurements of these adipocytes were also 
performed as described (31). Briefly, 0.43 ;jCi [U-^^Cj-glucose, 
72 ^g glucose and adipocytes were incubated with insulin or 
cinnamon fraction in a final reaction volume of 2 ml of Krebs-
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Ringer phosphate buffer, pH 7.1. After quantitation of ^^C02 
release of the cells in response to insulin or cinnamon 
fraction, an insulin activity ratio was determined. The insulin 
activity ratio was calculated by dividing the cpm of 1^C02 
released by the cells in the presence of insulin or cinnamon 
fraction by that of fat cells alone. Control cells not treated 
with insulin or cinnamon exhibit an insulin activity ratio of 
one, which indicates an absence of biological activity (31). 
Mass spectrometry Electron impact and chemical 
ionization mass spectra were performed on a TSQ700 Finnigan MAT 
(San Jose, CA) mass spectrometer using Qi only as a mass 
analyzer at the Instrument Services Laboratories at Iowa State 
University. Electron energy and current emission were 
maintained at 70 eV and 400 /vA, respectively, while the source 
temperature was maintained at 150°C. Samples were introduced 
via a solids probe. Chemical ionization experiments were 
conducted using ammonia gas as reagent gas. Odd electron 
moecular ions were observed in the electron impact mass spectra 
while, in chemical ionization mass spectra, protonated and 
ammonia adduct ions were observed. 
Results 
Survey of potential PTP-1 inhibitors A series of gel 
filtration fractions from cinnamon extract, along with a series 
of chromium compounds, were tested for the ability to inhibit 
rat brain PTP-1. As shown in Figure 1, most of the chromium 
Figure 1. Survey of potential PTP-1 inhibitors: chromium compounds and cinnamon 
fractions. PTP-1 activity was measured using ^^p.^c^M.^ygozyme as substrate 
(see Experimental Procedures) in the absence (C-control) or presence of 
chromium compound or cinnamon fraction. (1) chromium nicotinate, 2.5 mg/ml; 
(2) chromium-nicotinate-glycine-galactose-cysteine, 0.8 mg/ml; (3) chromium 
picolinate, 1.6 mg/ml; (4) chromium picolate, 3.3 mg/ml; (5) chromium 
chloride, 10 mM; (6) 59301A; (7) 109301F; (8) F5257; (9) KG; (10) HPBY. The 
concentrations of chromium compounds described are final concentrations in 
the assay. Those concentrations were chosen to give the greatest soluble 
concentration possible in the assay. The final dilution of each of the 
cinnamon fractions in the PTP-1 assay was 1:6. 
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compounds were not able to inhibit PTP-1 phosphatase activity. 
Although CrCl3 was able to inhibit PTP-1, it has been previously 
shown not to be biologically active in the rat epididymal fat 
cell assay (26). Therefore, we did not consider its PTP-1 
inhibitory properties to be of interest for these purposes. In 
contrast to the chromium compounds, all of the fractions from 
cinnamon were found to inhibit PTP-1, for a 1:6 dilution in the 
assay. We then wanted to characterize further and compare how 
well each fraction from cinnamon, plus the inhibitory chromium 
nicotinate compound, inhibited PTP-1. The inhibitory dilution 
dependence curves for these fractions are shown in Figure 2. It 
appears from these curves that cinnamon fraction 109301F shows 
greater inhibition of PTP-1 activity at higher dilutions than 
the other fractions, although it must be noted that the relative 
concentrations of the inhibitory substance(s) is unknown in all 
the fractions. Because of this apparent ability to inhibit PTP-
1 activity and the fact that this fraction also potentiated 
insulin's biological activity in the epididymal fat cell assay 
better than any of the other fractions (data to be presented 
elsewhere) we chose to work with 109301F and attempt to 
characterize its role in insulin potentiation. 
Effect of 1Q9301F on phosphatases other than PTP-1 We 
tested the effect of 109301F on the phosphatase activities of 
alkaline phosphatase (37) and the calmodulin-activated 
phosphatase calcineurin (38,39). 109301F does not inhibit these 
phosphatases (Table I), with no effect on alkaline phosphatase 
Figure 2. Inhibition dilution dependence curves for 
inhibition of PTP-1 by chromium nicotinate and 
cinnamon fractions. PTP-1 activity was assayed in 
the presence of serial dilutions of the inhibitors 
determined from Fig. 1. (•) chromium nicotinate 
dilutions from 2.5 mg/ml stock); (•) 59301A; (A) 
109301F; (•) KG; (•) F5257; (O) HPBY. 
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Table I. Effect of cinnamon fraction 109301F on phosphatase 
activities of alkaline phosphatase and calcineurin. Notes. (A) 
Alkaline phosphatase activity was measured in the absence or 
presence of a final dilution of 1:50 109301F. Using 0.75 mM 
pNPP as substrate, alkaline phosphatase was assayed continuously 
by monitoring p-nitrophenol formation at 410 nm in a Beckman DU-
7 spectrophotometer. Assays were done in 1.0 M Tris, pH 8.0, 
with 0.4 pg/ml alkaline phosphatase. (B) Calcineurin activity 
was measured in the absence or presence of a final dilution of 
1:30 in the assay. Calcineurin was assayed using pNPP as 
substrate as described (46). 
(A) alkaline phosphatase 
control 
109301F 
umol/min/mq 
60.0 ± 4.9 
59.5 ± 2.8 
(B) calcineurin 
control 
109301F 
nmol/min/mq 
39.5 ± 4.8 
74.5 ± 5.6 
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activity and activation of calcineurin activity. This indicates 
that 10930IF may be a specific protein tyrosine phosphatase 
inhibitor. 
Kinetics of inhibition and time dependent inactivation of 
PTP-1 by 109301F If 109301F acted to inhibit PTP-1 activity 
by binding to the active site, then one would expect that the 
inhibitory effect of 109301F could be competed out with 
substrate and show kinetics competitive with respect to 
substrate. Figure 3 shows that 109301F is instead 
noncompetitive with respect to substrate. 
To examine the possibility that 10930IF could cause a time 
dependent inactivation of PTP-1, the enzyme and 109301F were 
incubated together at 30°C and diluted out at different times 
during the course of the incubation. The diluted enzyme from 
the different time points was then assayed without inhibitor. 
The final concentration of 109301F in the assay was such that no 
inhibition of PTP-1 in a separate control was observed (data not 
shown). Figure 4 shows that a time-dependent, irreversible 
inactivation of PTP-1 indeed results upon incubation of PTP-1 
with 109301F. A very fast inactivation of PTP-1 seems to occur 
within the first five minutes of incubation with 109301F, while 
a slower inactivation occurs through 30 minutes of incubation. 
This suggested that the inactivation of PTP-1 by 109301F may be 
due to more than one inhibitory substance in the fraction. 
These results also suggest that irreversible inactivation of the 
enzyme obfuscates the interpretation of the kinetics of Fig. 3. 
Figure 3. Kinetics of inhibition of PTP-1 by 109301F. PTP-1 
activity was measured using a range of 25-1000 nM 
32p_RCMM-lysozyme in the absence of inhibitor (•) 
or in the presence of a final dilution of 1:100 
(•) and 1:300 (A) 109301F. 
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Figure 4. Time-dependent, irreversible inactivation of PTP-1 
upon incubation with 109301F. PTP-1 and 109301F 
(•) were preincubated together at 30°C at 1:3500 
and 1:150, respectively. (•) is the PTP-1 control 
preincubated in assay buffer only. At the 
indicated times, an aliquot of the preincubation 
mixtures were diluted 1:100 and placed on ice 
until the diluted enzyme was assayed. 20 ;j1 of 
diluted enzyme was used in a typical PTP-1 assay 
(see Experimental Procedures). The final 
concentration of 109301F which carried over into 
the PTP-1 assay after dilution from the 
preincubation mixture was 1:45000. This 
concentration of 109301F did not inhibit freshly 
added PTP-1 which was not preincubated with 
109301F (data not shown, see also Fig. 2). 
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Non-competitive inhibition normally might be interpreted to mean 
that binding of the inhibitor is occuring outside the active 
site region. However, if binding did occur in the active site 
and caused partial irreversible inactivation of the enzyme, the 
results of Fig. 3 would be expected. 
To determine if this irreversible inactivation was taking 
place at the active site of PTP-1, arsenate, a competitive 
inhibitor of PTP-1 (Ki = 0.24 mM (47)), was included in the 
preincubation of PTP-1 with the void fraction. Addition of 1 mM 
arsenate during the preincubation results in only 71% inhibition 
of PTP-1 after 30 minutes of preincubation vs. 97% inhibition of 
PTP-1 without arsenate (data not shown). This partial 
protection of PTP-1 from inactivation by the void fraction in 
the presence of the competitive inhibitor arsenate may indicate 
that the inhibitor is acting at the active site of the enzyme. 
Sephadex G-25 chromatography of 109301F-B Because the 
inactivation of PTP-1 by 109301F may have been due to more than 
one inhibitory substance (Fig. 4), an attempt was made to 
separate these possible components. 20 ml of the 109301F-B 
fraction from the second Sephadex G-50 chromatography run with 
sulfite was concentrated in a Savant speed vacuum to 
approximately 1 ml, then 0.5 ml of this concentrated fraction 
chromatographed on a 25 x 1 cm Sephadex G-25 gel filtration 
column. The resulting separated peaks in order of their elution 
are illustrated in Figure 5. They were labeled the "void", 
"red", and "yellow" peaks, because the orange-brown peak came 
Figure 5. Sephadex G-25 chromatography of 109301F. The 
1093OIF fraction in bisulfite buffer was 
concentrated in a Savant speed vacuum to 
approximately 1 ml. The fraction was then 
chromatographed on a 25 x 1 cm Sephadex G-25 gel 
filtration column, using ddH20 as buffer. The 
resulting separated peaks are shown in order of 
their elution. 
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out in the void volume and the other two peaks were red and 
yellow in color. 
We were concerned that, since the red and yellow peaks 
eluted rather late in the Sephadex G-25 chromatography, these 
peaks could have co-eluted with the low molecular weight sulfite 
from the sulfite buffer. Therefore, we qualitatively tested 
this by adding H2O2 to oxidize any sulfite present to sulfate, 
then we added BaCl2 to precipitate any sulfate present as BaS04. 
Using this test we found no sulfite present in the void 
fraction, as expected. However, the yellow and red fractions, 
having been concentrated 10-fold after elution from Sephadex G-
25, contained <60 mM sulfite, based on spectral data obtained at 
the absorbance maximum of sulfite (A276) with standard solutions 
of known sulfite concentrations (not shown). This estimation 
was also corroborated by comparison of the BaS04 precipitate to 
a known amount of sulfite (data not shown). Because of the 
limiting quantity of the red fraction, we decided to further 
characterize only the void fraction and cautiously continue 
characterization of the yellow fraction. We describe control 
experiments in which enzyme activities were measured in the 
presence of sulfite where appropriate in this text. 
Inhibition of PTP-1 by the yellow fraction Both of the 
yellow and void peaks from the Sephadex G-25 chromatography 
inhibit PTP-1 (Table II) and are biologically active (data to be 
presented elsewhere). The inhibition of PTP-1 by the yellow 
fraction using ^^p.RCj^M-lysozyme as substrate (Table IIA) is 
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Table II. Inhibition of PTP-1 by fractions from Sephadex G-
25 chromatography. Notes. (A) PTP-1 activity was measured 
in the absence (control) or presence of a final dilution of 
1:6 void or yellow fraction using 32p_RCMM-lysozyme as 
substrate. The final concentration of sulfite carried over 
from the yellow fraction was <10 mM sulfite. (B) PTP-1 
activity was measured in the absence (control) or presence of 
a final dilution of yellow or void fraction as indicated, 
using 10 mM pNPP as substrate. The final concentration of 
sulfite carried over from the yellow fraction in the 1:12 and 
1:120 dilutions was <5 mM and <0.5 mM, respectively. 
(A) 3^P-RCMM-lvso2vme 
control 
1.0 mM sulfite 
6.6 mM sulfite 
1;6 void 
1:6 yellow 
% activity 
100 
63.3 
10.3 
0 . 0 *  
2.3 
(B) PNPP 
control 
10.0 mM sulfite 
1:12 void 
1:12 yellow 
1:120 yellow 
% activity 
100 
101 
7.3 
14.7 
29.8 
*no counts above background could be detected 
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complicated by the fact that the assay contains <10 mM sulfite 
carried over from the dilution of the yellow fraction. This is 
because only 6.6 mM sulfite in the assay inhibits the 
dephosphorylation of ^2p_RCMM-lysozyme by PTP-1 by 90%. In 
contrast, when we used the low molecular weight substrate pNPP 
at the saturating concentration of 10 mM (Km = 3.5 mM (36)), 10 
mM sulfite was found not to inhibit PTP-1 (Table IIB). The 
yellow fraction at a final dilution of 1:12 and a contaminating 
concentration of sulfite of <5 mM inhibited PTP-1 activity by 
85%. Therefore, the yellow fraction does contain at least one 
component which inhibits PTP-1, and this inhibition is not due 
to sulfite. This was not observed using 32p_RCMM-lysozyme as 
substrate, probably because saturating substrate was not used in 
these assays. 
Inhibitory dilution dependence curve for inhibition of PTP-
1 by the void peak The orange-brown color of the void peak 
most closely resembles that of the 109301F fraction. Therefore, 
we wanted to determine if the inhibitory dilution dependence of 
the void peak was similar to that of the 109301F fraction. As 
shown in Figure 6, the dilution dependence of the PTP-1 
inhibitory property of the void peak does closely resemble that 
of the 109301F fraction in Figure 2. 
Effect of preincubation of Sephadex G-25 peaks with PTP-1 
To determine which Sephadex G-25 peak was capable of 
inactivating PTP-1 in a time-dependent manner, the experiment in 
Figure 4 was repeated with the yellow and void fractions from 
Figure 6. Inhibition dilution dependence curve for 
inhibition of PTP-1 by the void fraction. 
Inhibition dilution dependence curve of inhibition 
of PTP-1 by the void fraction was determined as in 
Figure 2, using only the void fraction from 
Sephadex G-25 chromatography as inhibitor. 
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Sephadex G-25 chromatography. As shown in Figure 7, incubation 
of PTP-1 with only the void peak shows inactivation of PTP-1 in 
a time-dependent manner. Therefore, we conclude that at least 
one substance in 109301F that is responsible for the time-
dependent inactivation of PTP-1 is in the Sephadax G-25 void 
fraction. 
Kinetics of inhibition of PTP-1 by Sephadex G-25 void peak 
Since it was apparent that some components in 109301F had been 
separated from each other during Sephadex G-25 chromatography, 
kinetic analysis of the void fraction was performed. The 
kinetics of void peak inhibition of PTP-1 shows 
noncompetitiveness with respect to substrate (Fig. 8). This 
again is reminiscent of the kinetics of the 109301F mixture, 
indicating that the noncompetitive kinetics exhibited by 109301F 
is probably due to the component(s) in the void peak. 
Effect of wortmannin on the insulin potentiating activity 
of cinnamon Wortmannin is an antifungal agent which inhibits 
PI 3'-kinase in the nanomolar range (40-41), which, in turn, 
inhibits many effects of insulin stimulation in insulin-
dependent cells (42). To determine if the insulin potentiating 
effects of cinnamon were affected by wortmannin, rat adipocytes 
were incubated with different amounts of the agent and the 
insulin response was measured in the presence 10930IF. Figure 9 
shows that the biological potentiation in response to both 
insulin and cinnamon is dramatically reduced as the 
concentration of wortmannin is increased. This indicates that 
Figure 1. Effect of preincubation of PTP-1 with yellow and 
void fractions. PTP-1, at a dilution of 1:3500, 
was incubated with the yellow (•) or void (O) 
fraction at a final dilution of 1:50 or 1:100, 
respectively. (•) is control PTP-1 preincubated 
in assay buffer only. At 2, 4, 6, 10, 15, and 30 
minutes, aliquots of each of the preincubation 
mixtures were diluted 1:100 and assayed as in 
Figure 4. The final dilution of inhibitor (yellow 
or void) in the preincubation mixture was chosen 
so that PTP-1 inhibition was 35-50% in a separate 
assay with that final dilution in the PTP-1 assay 
without preincubation or dilution to 1:100. 
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Figure 8. Kinetics of inhibition of PTP-1 by the void peak 
from cinnamon. PTP-1 activity was measured using 
a range of 25-1000 nM 32p_RCMM-lysozyme in the 
absence of inhibitor (•) or in the presence of a 
final dilution of 1:100 (•) and 1:200 (A) of the 
void fraction. 
-0.01 -
-0.005 r 
0 ^ 
0.005 -
\ 0.01 -C/3 
Z 0.015 -
S 0.02 -
n 
0.025 -
0.03 -
0.035 -
0.04 
1/Velocity 
U> 
o^ 
Figure 9. Wortmannin effects on adipocytes activated by cinnamon fraction 109301F or 
insulin. Fat cells were isolated as described (31) and incubated with the 
designated amounts of wortmannin. Wortmannin was dissolved in 
dimethylsulfoxide and 10 ptl of DMSO containing wortmannin were added to each 
tube. The purified cinnamon fraction 109301F (25 ^ 1, dry weight less than 1 
mg/ml, open bars), or porcine insulin (100 /jU/ml, closed bars) was added to 
tubes. Tubes contained 3.8 mg of total fat. 
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-the cinnamon fraction acts to signal through PI 3'-kinase in 
insulin-dependent cells. 
Effect of different cinnamon fractions on insulin receptor 
kinase Since inhibition of PI 3'-kinase inhibits cinnamon 
signalling, this suggests that the cinnamon fraction is acting 
upstream of PI 3'-kinase. The known upstream elements in 
activating PI 3'-kinase signalling in response to insulin are 
IRS-1 and the insulin receptor itself (43). Since we observed 
that 109301F inhibited PTP-1, which in vivo may result in the 
increased autophosphorylation of the insulin receptor kinase 
(13-15), we wanted to determine if 109301F had any direct effect 
on the catalytic autophosphorylation of the kinase. As shown in 
Figure lOA, 109301F directly activates the autophosphorylation 
of the insulin receptor kinase catalytic domain. However, this 
effect is transient, since preincubation of 109301F with the 
kinase for 30 minutes prior to addition of [y-32p]_atp results 
in basal level kinase autophosphorylation. The reason for this 
is unclear, but the activation is due to autophosphorylation on 
the kinase (Fig. lOB) and not to phosphorylation of the 
components in 109301F and those phosphorylated components 
binding to the P-81 paper in the assay. Therefore, since 
1093OIF inhibits PTP-1, a protein tyrosine phosphatase that may 
act in vivo to regulate the activity of the insulin receptor 
kinase, and activates the insulin receptor kinase 
autophosphorylation directly, this cinnamon fraction may act in 
vivo to do the same. The net result would be increased 
Figure 10. Effect of preincubation of insulin receptor kinase domain with 109301F on 
kinase autophosphorylation. 240 ^g/ml receptor kinase domain was 
preincubated with a final dilution of 1:150 10930IF for the indicated times, 
at which point 32p_j^TP was added to start a 5 minute autophosphorylation 
reaction. (A) The autophosphorylation reaction was terminated by addition 
of EDTA to 45 mM and then 15 of the reaction mixture was spotted onto P-
81 paper. Papers were washed and counted as described in the Experimental 
Procedures so that % incorporation of 32p into the kinase could be 
calculated. (B) 3.0 ^1 of 5X SDS gel loading buffer was added to 12 pi of 
the EDTA-terminated reactions from above and then heated at lOO^C for 3 
minutes. The samples were electrophoresed on a 12.5% SDS-PAGE gel, which 
was dried down and exposed to film for approximately 15 minutes. 
no 109301F + 109301F 
5 30 0 5 
time of preincubation (minutes) 
no 109301F + 109301F 
0  5  3 0  0  5  3 0  
(figure 10 continued) 
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autophosphorylation of the receptor kinase and presumably 
increased insulin signalling. 
After the void and yellow peaks were obtained from Sephadex 
G-25 chromatography, the effect of these peaks on the insulin 
receptor kinase catalytic domain was tested. Figure 11 shows 
the time course of the insulin receptor kinase 
autophosphorylation reaction in the presence of a 1:30 dilution 
of each peak. Both of the peaks activate kinase 
autophosphorylation, although the void peak appears to activate 
the kinase better than the yellow peak. It again must be noted 
that the concentration of the component(s) of these peaks is 
unknown, so comparison of the relevent activities is difficult. 
Activation of the receptor kinase by the yellow fraction is 
apparently not due to contaminating sulfite (estimated at <2 mM 
in the assay), since 6.6 mM sulfite had no effect on kinase 
autophosphorylation (data not shown). 
Since the autophosphorylation of the insulin receptor 
kinase is activated by these peaks from G-25 chromatography, we 
wanted to test the effect of the peaks on the kinase activity 
toward exogenous substrate. Unexpectedly, the insulin receptor 
kinase activity toward the exogenous substrate polyGluTyr (4:1) 
is inhibited in the presence of both G-25 peaks (Table III). 
However, it must be noted that the concentration of kinase in 
the polyGluTyr assay (20 fjq/val kinase) was such that no 
autophosphorylation of the kinase was possible. It is widely 
accepted that, in vivo, insulin acts to stimulate receptor 
Figure 11. Time course of receptor kinase autophosphorylation 
in the presence of the yellow and void fractions 
from cinnamon. 240 ^ ig/ml kinase domain was 
allowed to autophosphoirylate in the absence of 
cinnamon peak (•) or in the presence of a final 
dilution of 1:30 the yellow (A) or void (•) 
fractions. At the times indicated, the 
autophosphorylation reactions were terminated by 
spotting 15 /j1 of each reaction onto P-81 paper. 
Papers were washed and counted as described in the 
Experimental Procedures. 
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Table III. Effect of yellow and void fractions on receptor 
kinase activity toward exogenous substrate. Notes. Kinase 
activity toward polyGluTyr (4:1) was measured as described 
in the Experimental Procedures in the presence of a final 
dilution of 1:30 yellow or void fraction. 
sample pmol ^ T?/uq DolvGluTvr 
control 6.5 ± 0.3 
void 0.55 ± 0.18 
yellow 0.18 ± 0.06 
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kinase autophosphorylation, which, in turn, activates the kinase 
toward exogenous substrate. The cinnamon fraction 109301F does 
indeed increase autophosphorylation of the kinase, in assays 
where the concentration of kinase were such that 
autophosphorylation could take place (240 jug/ml kinase, in 
Figures 10 and 11). Therefore, if the role of 109301F in 
insulin signalling were to increase receptor 
autophosphorylation, then allowing the kinase domain to 
autophosphorylate first in the presence of the cinnamon fraction 
might result in increased activity of the kinase toward 
exogenous substrate. 
To examine this possibility, we incubated the insulin 
receptor kinase domain (240 jjg/ml) with one of the G-25 peaks, 
the yellow peak, and [Y-^^P]-ATP SO that increased 
autophosphorylation of the kinase could take place (Table IVA). 
Then, the autophosphorylated kinase was diluted (20 ^ /g/ml) to 
measure its activity toward exogenous substrate, in the presence 
and absence of additional yellow peak. The results are shown in 
Table IVB. Although kinase activity toward polyGluTyr (4:1) in 
the absence of additional yellow peak was not increased, the 
kinase activity toward polyGluTyr (4:1) in the presence of 
yellow peak showed a 2.5-fold increase over that of kinase not 
allowed to autophosphorylate in the presence of yellow peak 
(Table IVB). Therefore, increased autophosphorylation in the 
presence of the cinnamon yellow peak does increase its activity 
toward exogenous substrate, when assayed in the presence of the 
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Table IV. The effect of previous autophosphorylation of insulin 
receptor kinase domain in the presence of the yellow fraction 
from cinnamon. Notes. (A) 240 ^ g/ml receptor kinase was allowed 
to autophosphorylate for 5 minutes in the absence or presence of 
a final dilution of 1:30 of the yellow fraction, as described in 
Fig. lOA. (B) The autophosphorylated samples from (A) were 
diluted into a polyGluTyr assay to a final concentration of 20 
pg/ml kinase, "no yellow in assay" describes the kinase 
activity of both autophosphorylated samples (+ and - yellow 
fraction in the autophosphorylation reaction) toward polyGluTyr 
in the absence of additional yellow peak. "+ yellow in assay" 
describes the kinase activity of both autophosphorylated samples 
(+ and - yellow fraction in the autophosphorylation reaction) 
toward polyGluTyr with additional 1:30 yellow fraction included 
in the polyGluTyr assay. 
(A) Autophosphorylation of kinase domain 
(B) Kinase activity of above samples toward polvGluTvr M: 1) 
control 
with yellow peak 
% incorporation 
20.5 ± 4.6 
41.9 ± 3.0 
incorporation (pmol SZp/ua polyGluTyr) 
no yellow in assay 
control 21.8 ± 0.5 
23.2 ± 1.1 previous yellow 
+ yellow in assay 
control 0.292 ± 0.009 
0.692 ± 0.003 previous yellow 
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yellow peak. It is not clear why this difference is not 
observed when kinase autophosphorylated in the presence of the 
yellow peak, but assayed with polyGluTyr (4:1) in the absence of 
this peak. 
Partial chemical characterization and comparison of 
cinnamon peaks from Sephadex G-25 chromatography Absorbance 
spectra of the void and yellow peaks were taken to make 
comparisons of these fractions. As shown in Figure 12, the void 
fraction gives an absorbance at 320 nm in high pH, but the peak 
shifts to 291 nm and decreases in intensity in low pH. In 
contrast. Figure 13 shows that the yellow fraction, at pH 6.3, 
gives a small absorbance at 305 and 276 nm, but as pH is 
lowered, the 305 nm peak is lost while the intensity of the 27 6 
nm increases dramatically. 
Because a sulfite control solution also exhibits an 
aborbance peak at 276 nm which increases in intensity upon 
lowering the pH, it may appear that the absorbance of the yellow 
fraction at 276 nm is due solely to sulfite. However, 5 mM 
sulfite at pH 6.1 does not exhibit detectable absorbance at 276 
nm, while the absorbance of a dilution of 1:50 yellow fraction 
at pH 6.3 is 0.175 {not shown). The final concentration of 
sulfite in the diluted yellow fraction is only <1.33 mM. 
Therefore, some, but not all, of the absorbance at observed at 
276 nm in the yellow fraction is due to contaminating sulfite. 
The yellow fraction was then analyzed by both electron 
impact (EI) and chemical ionization (CI) mass spectrometry to 
Figure 12. Absorbance spectra of void fraction in base and acid. All absorbance 
spectra were taken with a BecJcman DU-7 spectrophotometer. Traces of void 
fraction in base are pH 11.2 and 12.0 (A320 peaks), while the traces in acid 
are pH 1.7, 1.9, and 2.2 (A291 peaks). 
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Figure 13. Absorbance spectra of the yellow fraction. An absorbance peak at 276 nm 
increased with decreasing pH. Traces, from the lowest A276 to highest A276/ 
are in pH 6.3, 3.2, 2.5, 2.3, 1.94. 
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determine the molecular weight of the compound. In electron 
impact mass spectrometry, the sample is bombarded by a stream of 
electrons, resulting in a molecular ion deficient in just one 
electron (M+'). EI analysis of the yellow fraction reveals a 
parent molecular ion of a molecular weight of 346 (Fig. 14A). 
We wanted to confirm this result, so the sample was also 
analyzed by chemical ionization mass spectrometry. In CI, the 
sample is ionized in the presence of reagent NH3 gas, so both 
ammonium adduct (MNH4"'") and protonated (MH+) parent molecular 
ions should be observed. This is indeed the case (Fig. 14B), 
with the ammonium adduct ion having a molecular weight of 364 
(346 + NH4''') and the protonated ion having a molecular weight of 
347 (346 + H"^). Therefore, a substance in the yellow fraction 
appears to have a molecular weight of 346. 
Discussion 
We have found that the cinnamon fraction 10930IF does 
inhibit PTP-1 activity, and that the PTP-1 inhibition is 
probably not due to the action of contaminating chromium. This 
is in accordance with the finding that chromium content in 
spices is not correlated with their insulin potentiating 
activity (30). The fraction 109301F, later found to be a 
mixture of components, also activates insulin receptor catalytic 
autophosphorylation. 
We have separated and identified two components derived 
from the cinnamon fraction 109301F, the yellow and void 
components, both of which inhibit PTP-1 activity and increase 
Figure 14.(A) Electron impact mass spectrometry of the yellow fraction. (B) Chemical 
ionization mass spectrometry of the yellow fraction. 
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insulin receptor kinase catalytic autophosphorylation. The 
mixture of these fractions (109301F) gives high biological 
response in the rat epidydimal fat cell assay. Wortmannin, a 
potent PI 3'-kinase inhibitor, decreases the biological 
responses to both cinnamon and insulin similarly, indicating 
that the cinnamon fraction is affecting elements upstream of PI 
3'-kinase. All these data may suggest that, in vivo, this 
mixture is acting to stimulate insulin receptor kinase activity 
while it inhibits PTPases which may attenuate the receptor 
kinase signal. 
The kinetic analysis of PTP-1 inhibition by the void 
fraction shows that it exhibits a time-dependent, irreversible 
inactivation of PTP-1 and is noncompetitive with respect to 
substrate. The irreversible inhibition of PTP-1 by the void may 
indicate that the compound(s) in the void fraction are 
covalently modifying the PTP-1. No shift in mobility on SDS-
PAGE was observed after PTP-1 incubation with and inactivation 
by the void (data not shown). However, since the identity of 
the inhibitor in this case is not known, nothing can be inferred 
about the lability of a possible covalent linkage between the 
void and PTP-1 during electrophoresis and/or in the presence of 
SDS. 
The yellow and void peaks both act to increase the 
autophosphorylation rate of the insulin receptor kinase, but 
this effect is transient. This is because preincubation of the 
kinase with the cinnamon fraction 109301F for 5 or 30 minutes 
159 
results in a kinase with a basal autophosphorylation rate. The 
yellow fraction also acts to increase receptor kinase catalytic 
activity toward exogenous substrate, but only if the kinase is 
allowed to first autophosphorylate in the presence of the yellow 
peak and then is diluted into the polyGluTyr assay in the 
presence of additional yellow peak. No increase in kinase 
exogenous substrate activity is observed if the polyGluTyr assay 
is performed in the absence of additional yellow peak, even if 
the kinase is allowed to first autophosphorylate in the presence 
of the yellow fraction. It is not clear why this is, but 
perhaps it is related to the transient effect of the cinnamon 
fraction 109301F on the kinase. As mentioned before, only a 5 
minute preincubation of the kinase with 109301F results in only 
basal autophosphorylation of the kinase. In the experiment 
described in Table III, the kinase was allowed to 
autophosphorylate for 5 minutes in the presence and absence of 
the yellow fraction, then the enzyme was diluted for analysis of 
activity toward polyGluTyr. Perhaps addition of more yellow 
peak in the polyGluTyr assay would be the only way to observe a 
difference in activity, since, at that point in the experiment, 
the cinnamon fraction had already been incubated with the kinase 
for 5 minutes. 
The transient nature of the cinnamon fraction 109301F on 
the kinase may indicate that a compound(s) in it may actually be 
reacting with the receptor kinase itself and, in turn, be 
increasing the kinase activity. However, this active cinnamon-
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kinase complex seems to be unstable, since prolonged stimulation 
of the kinase is not observed upon preincubation of it with 
109301F for 5 minutes. The instability of the complex may 
result in the dissociation of the kinase from the compound(s) 
and/or may change the complex so that it can no longer activate 
the kinase. The inactivation of the cinnamon fraction 109301F 
upon incubation is not likely due to the buffer components of 
the kinase assay. This is because pre-incubation of 109301F 
with kinase buffer for 30 minutes has no effect on its ability 
to activate receptor kinase autophosphorylation (data not 
shown). 
Recently there has been a report of a specific compound 
which reacts with the B-subunit of the insulin receptor and acts 
to increase its basal kinase activity toward exogenous 
substrate. Bernier et al. (44) used maleimidodibutyrylbiocytin 
(MBB) to biotinylate sulfhydryls on the J3-subunit of the human 
insulin receptor in permeabilized CHO/HIRc cells. The modified 
kinase exhibited a 2-fold increase in the basal kinase activity 
toward exogenous substrate- Perhaps the compound(s) from 
cinnamon is acting on the kinase similarly. 
We attempted to partially characterize the two peaks from 
Sephadex G-25 chromatagraphy. Electron impact and chemical 
ionization mass spectrometry of one of the fractions, the yellow 
fraction, show that it contains a compound with a molecular 
weight of 346. Further characterization of the chemical 
properties of this compound is in progress. 
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GEKERAL SUMMARY AND DISCUSSION 
In this dissertation, aspects of regulation of two protein 
phosphatases involved in signal transduction are described. The 
first phosphatase, calcineurin, has been shown to be involved in 
T-cell activation, since inhibition of calcineurin by 
immunosuppressant treatment inhibits lL-2 production, and, in 
turn, T-cell activation (37,39). Calcineurin is also presumed 
to be regulated by Ca2+ in vivo because CaN B, the small subunit 
of calcineurin, is a Ca2+-binding protein, and calmodulin, 
another Ca2+-binding protein, binds to and activates 
calcineurinin in a Ca2+-dependent manner (1,5,6). Therefore, we 
sought to better understand this Ca2+-activation of calcineurin 
by attempting to understand more about the mechanism of 
activation of calcineurin by calmodulin. 
Because most studies on the interaction between calmodulin 
and the enzymes which it activates have focused on the role of 
hydrophobic residues in the interaction (56-58,65-67), we 
decided to look at the role of the positively charged arginine 
residue in calcineurin-calmodulin interaction. Certain arginine 
residues in the C-terminal portion of bovine brain CaN A were 
converted to the neutral amino acid citrulline by the action of 
peptidylarginine deiminase. This resulted in loss of 
calcineurin phosphatase activity and decreased calmodulin 
activation of calcineurin due to an apparent reduced affinity of 
calmodulin for deiminated bovine brain calcineurin. Through 
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amino acid analysis of calcineurin which was protected from loss 
of activity upon deimination by addition of calmodulin, we found 
that one or possibly two arginines relevant to these observed 
effects were being modified by the deiminase. We conclude that 
at least one arginine in calcineurin is important for calmodulin 
binding and is likely located at the calmodulin binding site of 
the CaN A subunit. 
Because of this conclusion, further localization of this 
arginine residue(s) was necessary. To this end, a truncated 
form of rat brain calcineurin was expressed in Sf21 cells in 
which all the arginines in the C-terminus of CaN A, except for 
those in the previously defined calmodulin domain, were deleted. 
Interestingly, deimination of this truncated form of calcineurin 
resulted in the incorporation of 0.5 mol/mol less citrulline 
than the full-length expressed calcineurin and no loss of 
phosphatase activity. The reduced amount of citrulline in 
truncated calcineurin could be due to truncation of an arqi.nj.ne 
which is normally deiminated in full-length calcineurin. 
Therefore, deimination of an arginine not present in the 
truncated calcineurin may be responsible for the loss of 
activity and reduced calmodulin binding of the full-length rat 
and bovine brain calcineurins. 
Since, in the 14 kDa C-terminus of rat brain CaN A, no 
other arginines exist outside of the previously defined 
calmodulin binding or autoinhibitory domains, the decreased 
amount of citrulline in the truncated calcineurin might mean 
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that the additional arginine being modified in the full-length 
calcineurin is in its autoinhibitory region. If this is the 
case, then one might hypothesize that calcineurin may contain 
two calmodulin binding domains, the calmodulin binding domain as 
previously described by Kincaid and Martin (17) and the sequence 
corresponding to or overlapping the autoinhibitory domain as 
described by Hashimoto et al (18). There is precedence for 
calmodulin binding to two distinct sites on an enzyme; in the 
phosphorylase kinase catalytic subunit, the C-terminal region 
contains two distinct calmodulin sites which calmodulin binds 
simultaneously (204). The autoinhibitory domain even contains a 
sequence motif in which every fourth residue in the sequence is 
a basic residue. This is reminiscent of the basic amphiphilic 
a-helix motif to which calmodulin binds (59), although the 
calcineurin autoinhibitory domain is not a true amphiphilic 
helix. Perhaps calmodulin could bind to the second putative 
site on calcineurin because of the similarity of the 
autoinhibitory domain to the amphiphilic helix. It well known 
that specific sequences to which calmodulin will bind are not 
well defined, but show considerable sequence diversity (59). 
Another hypothesis which may be made concerning the 
activation of calcineurin by calmodulin is that the calmodulin 
binding and autoinhibitory domains of calcineurin may not be 
separated by 50-60 residues like previously thought (17,18,61), 
but may actually be overlapping. Perrino et al (205) and 
studies in this dissertation have shown that truncating CaN A so 
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that the previously defined autoinhibitory domain is deleted 
results in an enzyme which can be further activated by addition 
of calmodulin. This indicates that sequences N-terminal to the 
identified autoinhibitory domain also contain autoinhibitory 
properties. Therefore, the actual autoinhibitory domain of 
calcineurin may extend and be adjacent to the previously defined 
calmodulin binding domain of calcineurin. Because of this and 
the idea that calmodulin may bind not only to the previously 
described calmodulin binding domain of calcineurin but also its 
autoinhibitory domain, we speculate that the domain organization 
of the calmodulin binding and autoinhibitory regions of 
calcineurin may not be so different from that of other 
calmodulin-dependent enzymes. The calmodulin binding and 
autoinhibitory domains of calcineurin may overlap, as do those 
of smooth muscle myosin light chain kinase (smMLCK), CaM-kinase 
II, and the catalytic subunit of phosphorylase kinase 
(62,63,207). 
The second phosphatase described in this dissertation is 
PTP-1, a rat homolog of PTP-lB, a protein tyrosine phosphatase 
thought to be involved in the attenuation of the insulin signal 
(172,174,175). The activity of PTP-1 was found to be regulated 
by compounds derived from cinnamon, compounds which potentiate 
insulin's activity in the rat epididymal fat cell assay. One 
fraction derived from cinnamon, the void fraction, is an 
irreversible inactivator of PTP-1. Another fraction, the yellow 
fraction also inhibits PTP-1, but does not irreversibly 
169 
inactivate PTP-1. Therefore, the cinnamon compounds may be 
acting to increase insulin signalling by inhibiting a PTPase 
which normally dephosphorylates the insulin receptor or a 
subsequent protein in the insulin signalling pathway, resulting 
in down-regulation of the receptor signal. 
However, the cinnamon compounds not only act to inhibit 
PTP-1, but they also act to increase insulin receptor kinase 
catalytic domain autophosphorylation directly. Therefore, the 
cinnamon compounds may have a dual function in insulin 
signalling, causing stimulation of insulin receptor kinase 
autophosphorylation while inhibiting PTPases which would 
attenuate the kinase signal. Wortmannin decreases the 
biological potentiation of insulin by inhibiting PI 3'-kinase 
activity (114,115). In these studies, wortmannin was found to 
decrease the biological response to insulin and cinnamon 
similarly. This indicates that the cinnamon compounds are 
affecting element(s) in insulin signalling upstream of PI 3'-
kinase. Since insulin receptor kinase autophosphorylation is 
activated by the cinnamon compounds in vitro, the insulin 
receptor itself is a good candidate for an in vivo target for 
the cinnamon compounds. 
If the cinnamon compounds do have a dual role in insulin 
signalling, then the above wortmannin result implies that the 
relevant PTPase(s) would also be acting upstream of PI 3'-
kinase. The obvious possible substrates for this PTPase which 
are upstream of PI 3'-kinase are iRS-1 and the insulin receptor 
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kinase itself. Although IRS-1 is knovm to be dephosphorylated 
in vivo (146,147), nothing is known about the identity of the 
PTPase(s) involved. More is known about the dephosphorylation 
of the insulin receptor kinase. A strong candidate PTPase for 
the dephosphorylation of the receptor kinase and attenuation of 
the kinase signal in vivo is PTP-IB (172,174,175), which is 97% 
identical to the rat PTP-1 used in these studies. Perhaps one 
of the targets of the cinnamon compounds in the rat fat cell 
assay is PTP-lB. 
Studies now need to be undertaken to determine if these in 
vitro results suggesting that certain cinnamon compounds 
activate the insulin receptor kinase and inhibit a PTPase hold 
for in vivo systems. This may include the determination of the 
phosphorylation state of the receptor kinase and PTPase 
activities in adipocytes in response to these cinnamon 
compounds. This and further characterization of the identity of 
the cinnamon compounds responsible may lead to identifying 
another possible treatment for insulin resistance. 
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